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PREFACE
Chikungunya fever (CHIK) is an emerging, mosquito-borne disease caused by an alphavirus, Chikungunya virus (CHIKV). The disease is transmitted predominantly by Aedes aegypti and Ae. albopictus 
mosquitoes, the same species involved in the transmission of  dengue.
Traditionally, CHIKV epidemics have shown cyclical trends, with inter-epidemic 
periods ranging from 4 to 30 years. Since 2004, CHIKV has expanded its 
geographical range, causing sustained epidemics of  unprecedented magnitude 
in Asia and Africa. Although areas in Asia and Africa are considered to be 
endemic for the disease, the virus produced outbreaks in many new territories 
in the Indian Ocean islands and in Italy. This recent reemergence of  CHIKV 
has heightened the world’s public health awareness and concern about this virus.
Controlling the spread of  arthropod-borne viruses (arboviruses) in the Americas 
has not been very successful. Dengue continues to ravage many areas in the 
Americas, reaching as far north as the United States and as far south as Argentina. 
During	the	first	trimester	of 	2010,	several	dengue	virus	outbreaks	in	the	Region	
occurred at unprecedented rates for this time of  the year, especially in Central 
America and the Caribbean.
West Nile virus, another arbovirus recently introduced to the Americas, is 
now endemic in the Region. Over the last decade, West Nile virus has evolved 
epidemiologically and has expanded its geographic range in the Region from 
Canada to Argentina; in 2007, human and equine cases were detected in 
Argentina.	Moreover,	in	2010,	three	laboratory-confirmed	cases	of 	a	related	
vi vii
arbovirus, the Saint Louis encephalitis virus, were reported in children from 6 to 8 
years old in Argentina (the city of  Buenos Aires and the province of  Buenos Aires).
Although indigenous transmission of  CHIKV does not occur in the Americas 
now, the risk for its introduction into local vector mosquito populations is likely 
higher than had previously been thought, especially in tropical and subtropical 
areas where Ae. aegypti, one of  the main vectors of  CHIKV, has a broad 
distribution. The broad distribution of  competent vectors, coupled with the lack 
of  exposure to CHIKV of  the human population in the Americas, places this 
Region at risk for the introduction and spread of  the virus.  The resulting large 
outbreaks would likely tax existing health-care systems and the public health 
infrastructure, and could potentially cripple some of  society’s functioning.
Between	2006	and	2010,	106	laboratory-confirmed	or	probable	cases	of 	CHIKV	
were detected among travelers returning to the United States, compared to only 
3 cases reported between 1995 and 2005. There also have been nine imported 
CHIK cases reported in the French territories in the Americas since 2006-three 
in Martinique, three in Guadeloupe, and three in Guyana. To date, none of  the 
travel-related cases have led to local transmission, but these cases document 
an ongoing risk for the introduction and possible sustained transmission of  
CHIKV in the Americas.
 
There	is	no	specific	treatment	for	CHIKV	infection,	nor	any	commercially	
available vaccine to prevent it. Pending the development of  a new vaccine, the 
only effective means of  prevention are to protect individuals against mosquito 
bites. It should be noted, however, that the only available method for preventing 
an ongoing transmission of  a possible CHIKV epidemic, namely the control of  
its vectors, has rarely been achieved and never has been sustained.
Given these factors, the Pan American Health Organization (PAHO), with the 
support of  the Division of  Vector-borne Diseases of  the United States Centers 
for Disease Control and Prevention (DVBD, CDC), created a working group and 
convened a meeting in Lima, Peru, on July 21−23, 2010, to discuss the threat this 
virus represents and to examine measures that might be taken to mitigate this 
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threat (see Appendix I for additional details on the meeting). These preparedness 
guidelines are the result of  this collaboration.
These guidelines are intended to be adapted by each Member Country. They are 
designed to increase awareness about the threat and to provide the necessary 
tools to put in place the best possible strategies to prevent the importation 
of  CHIKV into the Region, or to control it if  introduced. These guidelines 
provide guidance on how to detect an outbreak of  the disease, conduct pertinent 
epidemiological investigations, and prevent or mitigate the spread of  the disease 
throughout the Region.
We encourage everyone working to apply these guidelines to take into account all the 
knowledge available and their own country’s capability to cope with the introduction 
of  CHIKV. Steps should be taken now to put in place the necessary measures that 
will decrease the impact that this new arbovirus could have in our Region.
Dr. Otavio Oliva
Advisor on Viral Diseases
Pan American Health Organization
Dr. José Luis San Martín
Advisor on Dengue
Pan American Health Organization
Dr. Roger S. Nasci
Chief, Arboviral Diseases Branch
U.S. Centers for Disease Control and Prevention 
viii ix
ACkNOwLEdgmENTS 
The contents of  this document were written by J. Erin Staples, Ann Powers, 
Kay Tomashek, Robert S. Lanciotti, Elizabeth Hunsperger, Jorge Munoz, Harry 
Savage, John-Paul Mutebi, Roberto Barrera, Emily Zielinski-Gutierrez, Carmen 
Perez, and Roger S. Nasci of  the DVBD, CDC with valuable review and revision 
by Otavio Oliva, José Luis San Martín, Luz María Vilca and the members of  the 
Technical Advisory Group shown in Appendix I. Sonia Uriona assisted in the 
guideline’s design and the Spanish translation.
The publication of  these guidelines was possible thanks to funding from the U.S. 
Centers for Disease Control and Prevention.
viii ix
ABBREviATiONS ANd 
ACRONymS
Ae. Aedes
BSL-3 Biosafety level 3
CAREC Caribbean Epidemiology Centre
CBC Complete blood count
CDC United States Centers for Disease Control and Prevention
CHIK Chikungunya fever
CHIKV Chikungunya virus 
CIRE Les Cellules de l’Institut de veille sanitaire en région
CPE Cytopathic effects
CSF	 Cerebrospinal	fluid
Ct Cutoff
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DVBD Division of  Vector-borne Diseases
EEE Eastern equine encephalitis
ELISA Enzyme-linked immunosorbent assay
FAQ Frequently asked question
GIS Geographic Information System
HHS U. S. Department of  Health and Human Services
HI Hemaglutination Inhibition
HSD/IR/D Area of  Health Surveillance and Disease Prevention and Control / 
 Alert and Response and Epidemic Diseases / Program for Dengue 
HSD/IR/V Area of  Health Surveillance and Disease Prevention  
 and Control / Alert and Response and Epidemic Diseases /  
 Program for Viral Diseases
IFA	 Immunofluorescence	assay
IgG Immunoglobulin G
xIgM Immunoglobulin M
IHR International Health Regulations
IRS Indoor residual sprays
IT Insecticide-treated
IVM Integrated vector management
JE Japanese encephalitis
JIC Joint Information Center
MAC-ELISA IgM antibody capture enzyme-linked immunosorbent assay
NAT	 Nucleic	acid	amplification	testing
NGO Non-Governmental Organization
NMRC United States Naval Medical Research Center
NMRCD United States Naval Medical Research Center Detachment
NSAID	 Non-steroidal	anti-inflammatory	agent
PAHO Pan American Health Organization
PCR Polymerase chain reaction
Pfu Plaque-forming unit
PHEIC Public Health Emergency of  International Concern
PIO	 Public	Information	Officer
PRNT Plaque reduction neutralization test
PWR/PAN Pan American Health Organization,  
 World Health Organization Representative/Panama
RELDA Red de laboratorios de dengue de las Américas
RNA Ribonucleic acid
RT-PCR Reverse transcriptase-polymerase chain reaction
SFV Semliki Forest virus
SLE St. Louis encephalitis
SMS Short Message Service
TMB Tetramethylbanzidine base
THAN Travel health alert notice
VEE Venezuelan equine encephalitis
WEE Western equine encephalitis
WHO World Health Organization
WHOCC World Health Organization Collaborating Centre
WHOPES World Health Organization Pesticide Evaluation Scheme
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1. BACKGROUND AND 
RATIONALE
Since 2004, Chikungunya virus (CHIKV) has been causing large epidemics of  
chikungunya fever (CHIK), with considerable morbidity and suffering. The 
epidemics have crossed international borders and seas, and the virus has been 
introduced into at least 19 countries by travelers returning from affected areas. 
Because the virus has been introduced into geographic locations where the 
appropriate vectors are endemic, the disease could establish itself  in new areas of  
Europe and the Americas. The possibility that CHIKV could become established 
in the Americas has heightened awareness of  the need to develop guidelines 
for the prevention and control of  CHIK in PAHO’s Member Countries. This 
document is meant to serve as a guideline that individual countries can use as the 
basis for their CHIKV surveillance, prevention, and control programs.
TARGET OF  THESE GUIDELINES:
These	guidelines	are	intended	to	be	used	by	health	workers,	public	health	officials,	
and vector control specialists at the national, district, and sub-district levels.
OBJECTIVES:
General objectives are the prevention, detection, and timely response to 
outbreaks of  CHIK through surveillance, case detection, investigation, and the 
launching of  public health actions.
2. EPidEmiOLOgy
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CHIKV is an RNA virus that belongs to the Alphavirus genus in the family Togaviridae. The name chikungunya 
derives from a word in Makonde, the language spoken by the Makonde ethnic 
group living in southeast Tanzania and northern Mozambique. It roughly means 
“that which bends,” describing the stooped appearance of  persons suffering 
with the characteristic painful arthralgia. 
Epidemics of  fever, rash, and arthritis resembling CHIK were reported as 
early as the 1770s. However, the virus was not isolated from human serum and 
mosquitoes until an epidemic in Tanzania in 1952−1953.1 Subsequent outbreaks 
occurred in Africa and Asia, many of  them affecting small or rural communities. 
In Asia, however, CHIKV strains were isolated during large urban outbreaks in 
Bangkok, Thailand, in the 1960s and in Calcutta and Vellore, India, during the 
1960s and 1970s.2, 3
Recent Outbreaks
After the initial identification of  CHIKV, sporadic outbreaks continued to 
occur, but little activity was reported after the mid-1980s.  In 2004, however, an 
outbreak originating on the coast of  Kenya subsequently spread to Comoros, 
La Réunion, and several other Indian Ocean islands in the following two years. 
From the spring of  2004 to the summer of  2006, an estimated 500,000 cases 
had occurred.
4The epidemic spread from the Indian Ocean islands to India, where large 
outbreaks occurred in 2006. Once introduced in India, CHIKV spread to 17 
of  the country’s 28 states, infecting more than 1.39 million people before the 
end of  the year. The outbreak in India continued into 2010, with new cases 
appearing in areas that had not been affected in the epidemic’s early phase. 
Viremic travelers also spread outbreaks from India to the Andaman and Nicobar 
Islands, Sri Lanka, the Maldives, Singapore, Malaysia, Indonesia. Concern 
over the spread of  CHIKV peaked in 2007, when the virus was found to 
be spreading autochthonously (human-to-mosquito-to-human) in northern Italy 
after being introduced by a viremic traveler returning from India.4 The attack 
rates in communities that have been affected in the recent epidemics ranged 
from 38%−63%, and in many of  these countries cases continue to be reported, 
albeit at reduced levels. In 2010, the virus continued to cause illness in India, 
Indonesia, Myanmar, Thailand, and the Maldives; it also has resurged in La 
Réunion.	In	2010,	imported	cases	also	were	identified	in	Taiwan,	France,	and	
the United States.  These cases were infected viremic travelers returning from 
Indonesia, La Réunion, and India, respectively.
During the recent outbreaks, individuals viremic with CHIKV were found in 
the Caribbean (Martinique), the United States, and French Guiana.5  All of  them 
had returned from areas with endemic or epidemic CHIKV transmission; thus, 
these cases were not due to autochthonous transmission. All of  these areas have 
competent mosquito vectors and naïve hosts, however, and thus could support 
endemic transmission of  CHIKV in the Americas. Given these factors, CHIKV 
has the capacity to emerge, re-emerge, and quickly spread in novel areas, which 
makes heightened surveillance and preparedness a priority.
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Transmiss ion  Dynamics
Vectors
There are two main vectors of  CHIKV, Aedes aegypti and Ae. albopictus. Both 
mosquito species are widely distributed throughout the tropics with Ae. albopictus 
also present at more temperate latitudes. Given the vectors’ distribution 
throughout the Americas, the entire Region is susceptible to the virus’ invasion 
and spread.  
Reservoirs
Humans serve as the primary CHIKV reservoir during epidemic periods. During 
inter-epidemic periods, several vertebrates have been implicated as potential 
reservoirs, including non-human primates, rodents, birds, and some small 
mammals.
Incubation Periods
Mosquitoes acquire the virus from a viremic host.  Following an average 
extrinsic incubation of  10 days, the mosquito is then able to transmit the virus to 
a naïve host, such as a human. In humans bitten by an infected mosquito, disease 
symptoms typically occur after an average intrinsic incubation period of  three-
to-seven days (range: 1−12 days) (Figure 1). 
6Figure 1. Extrinsic and intrinsic incubation periods 
for Chikungunya virus.
Susceptibility and Immunity
All individuals not previously infected with CHIKV (naïve individuals) are at risk 
of  acquiring infection and developing disease. It is believed that once exposed 
to CHIKV, individuals will develop long lasting immunity that will protect them 
against reinfection. 
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7Summary of Epidemiology Section
•	 CHIKV is an RNA virus that belongs to the Alphavirus genus in the 
family Togaviridae.
•	 The attack rates in communities that have been affected in the 
recent	epidemics	ranged	from	38%−63%.
•	 The two major vectors of CHIKV are Ae. aegypti and Ae. albopictus; 
both mosquitoes are widely distributed throughout the tropics 
and Ae. albopictus is present at more temperate latitudes.
•	 CHIK is not known to be circulating in the Americas; however, the 
risk of introduction is high due to travel importation, competent 
vectors (same vectors as dengue), and population susceptibility.
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3. CLiNiCAL
3A. Clinical Presentation of Acute disease
Following the bite of  a mosquito infected with CHIKV, most individuals will 
present with symptomatic disease after an incubation period of  three to seven 
days (range: 1−12 days). Not all individuals infected with the virus develop 
symptoms, however. Serosurveys indicate that between 3% and 28% of  persons 
with antibodies to CHIKV have asymptomatic infections.6−7 Individuals 
acutely infected with CHIKV, whether clinically apparent or asymptomatic, can 
contribute to the spread of  the disease if  the vectors that transmit the virus are 
present and active in the same location.
CHIKV can cause acute, subacute, and chronic disease. Acute disease is most 
often characterized by sudden onset of  high fever (typically greater than 102°F 
[39°C]) and severe joint pain.8−10 Other signs and symptoms may include 
headache, diffuse back pain, myalgias, nausea, vomiting, polyarthritis, rash, and 
conjunctivitis (Table 1).11 The acute phase of  CHIK lasts for 3−10 days.
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Table 1.   Frequency of acute symptoms of CHIKV Infection.a
Symptom or sign
Frequency range
(% of symptomatic patients)
Fever 76−100
Polyarthralgias 71−100
Headache 17−74
Myalgias 46−72
Back pain 34−50
Nausea 50−69
Vomiting 4−59
Rash 28−77
Polyarthritis 12−32
Conjunctivitis 3−56
aTable compiled from a number of different studies.8,	9,	12-17 
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•	 Fever typically lasts from several days up to a week. The fever can be continu-
ous or intermittent; a drop in temperature is not associated with worsening of  
symptoms, however. Occasionally, the fever may be associated with relative 
bradycardia. 
•	 Joint symptoms are usually symmetric and occur most commonly in hands and 
feet, but they can affect more proximal joints. Swelling can also be seen and is 
often associated with tenosynovitis. Patients are often severely incapacitated due 
to pain, tenderness, swelling, and stiffness. Many patients cannot perform normal 
tasks	or	go	to	work,	and	many	will	be	confined	to	bed	due	to	these	symptoms.
•	 Rash	usually	occurs	two	to	five	days	after	onset	of 	fever	in	approximately	half 	
of  all patients. It is typically maculopapular, involving the trunk and extremi-
ties, but can also include palms, soles, and face. The rash can also present as a 
diffuse erythema that blanches with pressure. In infants, vesiculobullous lesions 
are often the most common skin manifestation.
There	are	no	significant	pathognomonic	hematologic	findings	seen	with	CHIKV	
infections. Abnormal laboratory findings can include mild thrombocytopenia 
(>100,000/mm3), leukopenia, and elevated liver function tests. Erythrocyte sedi-
mentation rate and C-reactive protein are usually elevated.
Rarely, severe forms of  the disease can occur with atypical manifestations (see 
Section 3B). Fatalities related to CHIKV infection are thought to be uncommon. 
However, an increase in crude death rates was reported during the 2004−2008 
epidemics in India and Mauritius.18, 19 
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Clinical presentation. Acute disease.
A. Edematous rash of the face B. Edematous poylarthritis of the hands 
C.  Erythema that blanches with pressure  
 
D. Periarticular swelling and joint  
effusion in knees 
E. Maculopapular rash in trunk and 
extremities 
F. Maculopapular rash in extremities, 
including palms
G. Bullous lesions in infant leg H.	Infant	with	maculo-papular	rash,	
petechial spots and erythema of upper 
and lower limbs associated with edema  
of the extremities
12
13
Clinical presentation. Subacute and chronic disease.
I. End of the acute stage. Swollen hands 
and	fine	desquamation
K. Tenosynovitis in hands
M. Elbow hygroma N. Swollen and stiff hands in 
a	55-year-old	man	who	was	
infected	5	years	earlier
J. Hyperpigmentation 
L. Tenosynovitis in ankle
Credits:
(A), (N) Pr. Fabrice Simon. Department of Infectious 
Diseases and Tropical Medicine. Laveran Military 
Teaching Hospital. Marseille, France. Previously pub-
lished in: Simon	F,	Javelle	E,	Oliver	M,	Leparc-Goffart	
I, Marimoutou C. Chikungunya virus infection. Curr 
Infect	Dis	Rep.	2011	Jun;13	(3):218-28.
(B) Pr. Fabrice Simon. Department of Infectious Dis-
eases and Tropical Medicine. Laveran Military Teach-
ing Hospital. Marseille, France. Previously published 
in: Simon	F.	et	al.	Chikungunya	 infection:	an	emerg-
ing rheumatism among travelers returned from Indian 
Ocean	islands.	Report	of	47	cases.	 	Medicine	(Balti-
more).	2007	May	;86(3):123-37.
(C), (D), (I), (K), (L), (M) Pr. Fabrice Simon. Department 
of Infectious Diseases and Tropical Medicine. Laveran 
Military Teaching Hospital. Marseille, France
(E), (G), (J) Dr.Bernard Lamey and Dr. Sophie Fite. 
Dermatologists. Société Réunionnaise de Derma-
tologie – Groupe Nord. France. Previously published 
in: 	Lamey	B,	Fite	S.	Fièvre	de	Chikungunya:	formes	
cliniques et manifestations dermatologiques. Nouv. 
Dermatol.	2007;26	:66-74
(F) Dr.Bernard Lamey and Dr. Sophie Fite. Dermatolo-
gists. Société Réunionnaise de Dermatologie. Groupe 
Nord. France. 
(H) Dr. Stéphanie Robin and Dr. Duksha Ramful, Service 
de	Pédiatrie,	CHR	Félix	Guyon,	Saint-Denis	de	La	Réunion
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3B. Atypical manifestations
Although most CHIKV infections result in fever and arthralgias, atypical 
manifestations can occur (Table 2). These manifestations can be due to the direct 
effects of  the virus, immunologic response to the virus, or drug toxicity.   
Table 2.  Atypical manifestations of CHIKV infection.
System Clinical manifestations
Neurological
Meningoencephalitis, encephalopathy, 
seizures,	Guillain-Barré	syndrome,	cerebellar	
syndrome, paresis, palsies, neuropathy
Ocular
Optic neuritis, iridocyclitis, episcleritis, 
retinitis, uveitis
Cardiovascular
Myocarditis, pericarditis, heart failure, 
arrhythmias, hemodynamic instability
Dermatological
Photosensitive hyperpigmentation, 
intertriginous	aphthous-like	ulcers,	
vesiculobullous dermatosis
Renal Nephritis, acute renal failure
Other
Bleeding dyscrasias, pneumonia, respiratory 
failure, hepatitis, pancreatitis, syndrome 
of inappropriate secretion of antidiuretic 
hormone (SIADH), hypoadrenalism
Adapted from Rajapakse et al. 20
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Some of  the atypical manifestations are more in common in certain groups. 
For instance, meningoencephalitis and vesiculobullous dermatosis are observed 
more frequently in children and infants, respectively..21, 22
3C. High-risk groups
CHIKV can affect women and men of  all ages. Clinical presentation is thought 
to vary by age, however, with the very young (neonates) and the elderly being 
at greater risk for more severe disease.23-26 In addition to age, comorbidities 
(underlying	diseases)	have	also	been	identified	as	a	risk	factor	for	poor	disease	
outcome.8, 23, 24, 27  
Most CHIKV infections that occur during pregnancy will not result in the virus 
being transmitted to the fetus.25, 28 There have been rare reports of  spontaneous 
abortions following CHIKV infection in the mother, however.26 The highest 
transmission risk appears to be when women are infected during the intrapartum 
period.29  The vertical transmission rate is as high as 49% during this period. 
Infants are typically asymptomatic at birth and then develop fever, pain, rash, 
and peripheral edema. Those infected during the intrapartum period may also 
develop neurologic disease (e.g., meningoencephalitis, white matter lesions, brain 
swelling, and intracranial hemorrhage), hemorrhagic symptoms, and myocardial 
disease.30 Laboratory abnormalities included raised liver function tests, reduced 
platelet and lymphocyte counts, and decreased prothrombin levels. Neonates 
who suffer from neurologic disease often develop long-term disabilities.31 There 
is no evidence that the virus is transmitted through breast milk.25
Older adults are more likely to suffer from severe atypical disease and death. 
Individuals >65 years had a 50-fold higher mortality rate when compared to 
younger adults (<45 years old).23 Although it is unclear why older adults are 
at increased risk for more severe disease, it may be due to the frequency of  
concomitant underlying diseases or decreased immunlogic response.23
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3d. differential diagnosis
Fever with or without arthralgia is a very common manifestation of  several 
other diseases. CHIK may not have the typical manifestations or it may coexist 
with other infectious diseases such as dengue fever or malaria. Diseases that 
can be considered in the differential diagnoses may vary based on pertinent 
epidemiologic features such as place of  residence, travel history, and exposure 
(Table 3).
Table 3.  Diseases or agents in the differential diagnosis of CHIK.
Disease or agent Presentation
Malaria
Periodicity of fever and alteration of 
consciousness
Dengue fever
Fever and two or more of the following, 
retro-orbital	or	ocular	pain,	headache,	
rash, myalgia, arthralgia, leucopenia, or 
hemorrhagic manifestations.  See section 
and table below for more information 
on dengue
Leptospirosis
Severe myalgia localized to calf muscles with 
conjunctival congestion/or subconjunctival 
hemorrhage with or without jaundice or 
oliguria.  Consider history of contact with 
contaminated water
Alphaviral infections 
(Mayaro, Ross River, 
Barmah Forest, O’nyong 
nyong, and Sindbis 
viruses)
Similar clinical presentation as CHIK; utilize 
travel history and known areas of Mayaro in 
the Americas
(Continued)
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Table 3.  Diseases or agents in the differential diagnosis of CHIK.
Disease or agent Presentation
Post-infectious	arthritis	
(including rheumatic 
fever)
Arthritis of one or more, typically larger 
joints due to an infectious disease such 
as Chlamydia, shigella, and gonorrhea.  
Rheumatic fever is seen more commonly 
in children as migratory polyarthritis 
predominantly affecting large joints.  
Consider antistreptolysin O (ASO) titer and 
history of sore throat with Jones criteria for 
rheumatic fever
Juvenile rheumatoid 
arthritis
Abrupt onset of fever and subsequent joint 
involvement in children
Over lap  and  Confus ion  w i th  Dengue  Fever :
CHIK has to be distinguished from dengue fever, which has the potential for 
much worse outcomes, including death. The two diseases can occur together in 
the same patient. Observations from previous outbreaks in Thailand and India 
have characterized the principal features distinguishing CHIK from dengue 
fever. In CHIK, shock or severe hemorrhage is very rarely observed; the onset is 
more acute and the duration of  fever is much shorter. In CHIK, maculopapular 
rash also is more frequent than in dengue fever (Table 4). Although people may 
complain of  diffuse body pain, the pain is much more pronounced and localized 
to the joints and tendons in CHIK, in comparison of  dengue fever.
(Cont.)
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Table	4.		Comparison of the clinical and laboratory features of 
chikungunya and dengue virus infections.a
Clinical and laboratory 
features
Chikungunya virus 
infection
Dengue virus 
infection
Fever	(>102°F	or	39°C) +++ ++
Myalgias + ++
Arthalgias +++ +/-
Headache ++ ++b
Rash ++ +
Bleeding dyscrasias +/- ++
Shock - +
Leukopenia ++ +++
Neutropenia + +++
Lymphopenia +++ ++
Elevated hematocrit - ++
Thrombocytopenia + +++
a Mean frequency of symptoms from studies where the two diseases were directly 
compared	among	patient	seeking	care;	 	+++	=	70-100%	of	patients;	++	=	40-
69%;	+	=	10-39%;	+/-	=	<10%;	-	=	0% 32, 33
b Often retroorbital
Table	modified	from	Staples	et	al.34
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3E. Subacute and Chronic disease
After	the	first	10	days,	most	patients	will	feel	an	improvement	in	their	general	
health and joint pain. Following this period, however, a relapse of  symptoms 
can occur, with some patients complaining of  various rheumatic symptoms, 
including distal polyarthritis, exacerbation of  pain in previously injured joints 
and bones, and subacute hypertrophic tenosynovitis in wrists and ankles.  This 
is most common two to three months after their illness onset. Some patients can 
also develop transient peripheral vascular disorders, such as Raynaud’s syndrome. 
In addition to physical symptoms, the majority of  patients will complain of  
depressive symptoms, general fatigue, and weakness.13
Chronic	disease	is	defined	by	symptoms	that	persist	for	more	than	three	months.	
The frequency of  persons reporting persistent symptoms varies substantially 
by study and the time that had elapsed between symptom onset and follow-up. 
Studies from South Africa note that 12%−18% of  patients will have persistent 
symptoms at 18 months and up to 2 to 3 years later.35, 36 From more recent studies 
in India, the proportion of  patients with persistent symptoms at 10 months 
was 49%.37  Data from La Réunion have found that as many as 80%−93% of  
patients will complain of  persistent symptoms 3 months after disease onset; this 
decreases to 57% at 15 months and to 47% at 2 years38, 39 (F. Simone, Dept of  
Infectious Diseases and Tropical Medicine, Laveran Military Hospital, Marseilles, 
France, personal communication). 
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The	most	common	persistent	symptom	is	inflammatory	arthralgias	in	the	same	
joints	that	were	affected	during	the	acute	stages.	Usually,	there	is	no	significant	
change in laboratory tests and x-rays of  the affected areas. However, some 
individuals will go onto develop destructive arthropathy/arthritis resembling 
rheumatoid or psoriatic arthritis.40  Other symptoms or complaints of  the chronic 
phase of  the disease can include fatigue and depression.6 Risk factors for non-
recovery are older age (> 45 years), pre-existing joint disorders, and more severe 
acute disease.38, 41  
Summary of Clinical Section
•	 Acute stage is symptomatic in most people and causes acute 
fever, distal polyarthralgias, and occasional rash.
•	 Severe and lethal forms are more frequent among patients older 
than	65	years	and/or	with	underlying	chronic	diseases.
•	 Maternal-fetal	transmission	is	possible	among	pregnant	women,	
with the highest risk for severe infection in the neonates during 
the antepartum period.
•	 Most patients initially will have severe and incapacitating joint 
symptoms;	many	will	go	on	to	develop	long-lasting	rheumatism,	
fatigue, and depression resulting in an impaired quality of life 
for months to years.
20
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4. LABORATORy
4A. Types of Laboratory Tests Available 
and Specimens Required
Three main types of  laboratory tests are used for diagnosing CHIK: virus 
isolation, reverse transcriptase-polymerase chain reaction (RT-PCR), and 
serology.  Samples collected during the first week after onset of  symptoms 
should be tested by both serological (immunoglobulin M [IgM] and G [IgG] 
ELISA) and virological (RT-PCR and isolation) methods. Specimens are usually 
blood or serum, but in neurological cases with meningoencephalitic features, 
cerebrospinal	fluid	(CSF)	may	also	be	obtained.	Limited	information	is	available	
for the detection of  virus by isolation or RT-PCR from tissues or organs. In 
suspected fatal cases, virus detection can be attempted on available specimens.
Selection of  the appropriate laboratory test is based upon the source of  the 
specimen (human or field-collected mosquitoes) and the time of  sample 
collection relative to symptom onset for humans.  
24
Vi rus  I so la t ion
Virus	isolation	can	be	performed	on	field	collected	mosquitoes	or	acute	serum	
specimens	(≤8	days).	Serum	obtained	from	whole	blood	collected	during	the	
first	week	of 	illness	and	transported	cold	(between	2°−8°C or dry ice) as soon 
as possible (within 48 hours) to the laboratory can be inoculated into a susceptible 
cell line or suckling mouse. CHIKV will produce typical cytopathic effects (CPE) 
within three days after inoculation in a variety of  cell lines, including Vero, BHK-
21,	and	HeLa	cells.		Virus	isolation	can	be	performed	in	T-25	flasks	or	shell	vials	
(see Appendix A). Recent data suggest that isolation in shell vials is both 
more	sensitive	and	produces	CPE	earlier	than	conventional	isolation	in	flasks.42 
CHIKV	isolation	must	be	confirmed	either	by	immunofluorescence	assay	(IFA),	
using	CHIKV-specific	antiserum,	or	by	RT-PCR	of 	the	culture	supernatant	or	
mouse brain suspension. Virus isolation must only be carried out in biosafety 
level 3 (BSL-3) laboratories to reduce the risk of  viral transmission.
RT-PCR
Several RT-PCR assays for the detection of  CHIKV RNA have been published. 
Real time, closed system assays should be utilized, due to their increased sensitivity 
and lower risk of  contamination. The Arboviral Diagnostic Laboratory within 
DVBD, CDC routinely utilizes the published assay in Appendix B,43 which 
demonstrates a sensitivity of  less than 1 pfu or 50 genome copies.  Serum from 
whole blood is used for PCR testing as well as virus isolation.
Sero logica l  Tes ts
For serological diagnosis, serum obtained from whole blood is utilized in enzyme-
linked immunosorbent assay (ELISA) and plaque reduction neutralization testing 
(PRNT).  The serum (or blood) specimen should be transported at 2°−8°C 
and should not be frozen. Serologic diagnosis can be made by demonstration 
of  IgM antibodies specific for CHIKV or by a four-fold rise in PRNT titer 
in	acute	and	convalescent	specimens.	IgM	antibodies	specific	for	CHIKV	are	
demonstrated by using the IgM antibody capture ELISA (MAC-ELISA),44 
followed by the PRNT (detailed protocols for IgM and IgG ELISAs shown in 
Appendix C). As of  2010, there were no World Health Organization (WHO) 
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validated	commercial	IgM	ELISAs	available.	PRNT	is	required	to	confirm	the	
MAC-ELISA results, since cross-reactivity in the MAC-ELISA between some 
members of  the Semliki Forest virus (SFV) serogroup has been observed. 
PRNT	testing,	whether	used	to	confirm	the	MAC-ELISA	or	to	demonstrate	
a four-fold rise in acute/convalescent specimens, should always include other 
viruses	within	the	SFV	serogroup	(e.g.,	Mayaro	virus)	to	validate	specificity	of 	
reactivity. In situations where the PRNT assay is not available, other serological 
tests (e.g. hemaglutination inhibition [HI]) can be used to identify a recent 
alphavirus	 infection;	however,	PRNT	is	required	to	confirm	a	recent	CHIKV	
infection.
An acute phase serum should be collected immediately after the onset of  illness 
and the convalescent phase serum 10−14	days	later.		CHIKV-specific	IgM	and	
neutralizing	antibodies	normally	develop	towards	the	end	of 	the	first	week	of 	
illness.	 	Therefore,	 to	definitively	rule	out	the	diagnosis,	convalescent	samples	
should be obtained on patients whose acute samples test negative.  
Col l ec t ion , S torage , and  Transpor ta t ion  o f  Samples
Proper collection, processing, storage, and transportation of  the specimens are 
essential aspects of  the laboratory diagnosis.
Collection of samples for serology, isolation and molecular diagnosis:
Sample: Serum
Time of collection: Acute,	within	the	first	eight	days	of 	illness;	convalescent,	
10−14 days after acute specimen collection.
To collect serum:
•	 Aseptically	collect	4−5 ml of  venous blood in a tube or a vial.
•	 Allow	blood	to	clot	at	room	temperature,	centrifuge	at	2,000	rpm	to	separate	
serum. Collect the serum in a clean dry vial.
•	 All	clinical	samples	should	be	accompanied	by	their	clinical	and	epidemiological	
information.
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Other types of specimens for laboratory investigation:
Specimens: 
•	 CSF	in	meningo-encephalitis	cases.
•	 Synovial	fluid	in	arthritis	with	effusion.
•	 Autopsy	material	–	serum	or	available	tissues.
[Note:	Mosquitoes	collected	 in	the	field	will	also	be	handled	using	the	same	
techniques described here]
Transportation of Samples:
•	 Transport	specimens	to	the	laboratory	at	2°−8°C (icebox) as soon as possible.
•	 Do	not	freeze	whole	blood,	as	hemolysis	may	interfere	with	serology	test	results.
•	 If 	a	delay	greater	than	24	hours	is	expected	before	specimens	can	be	submitted	
to the laboratory, the serum should be separated and stored at refrigerated 
temperature.
•	 Serum	samples	for	virus	isolation	and	molecular	diagnosis	should	be	stored	
frozen (at −20°C for short-term storage or at −70°C for long-term storage).
4B. Laboratory Surveillance
Prior	to	identification	of 	CHIKV	in	a	country,	laboratory	surveillance	should	be	
conducted on three sets of  samples, as follows: 1) dengue-negative specimens 
where the patient exhibits severe joint pain; 2) samples with clinically compatible 
illness from new geographic areas without active dengue circulation; 3) clusters 
of  febrile illness with severe joint pain. The following table (Table 5) outlines the 
ideal tests to be performed in various epidemiological settings.
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Table	5.	  Laboratory surveillance for Chikungunya virus 
by epidemiologic scenario.
Epidemiological 
scenario
Testing to be 
performed
Samples to test
No signs of  
transmission
IgM ELISA, IgG 
ELISA
All samples from patients 
exhibiting clinically 
compatible illness
Suspect CHIKV  
illness
IgM ELISA, IgG 
ELISA,	real-time	 
RT-PCR,	virus	
isolation, PRNT
All samples from patients 
exhibiting clinically 
compatible illness
Continued  
transmission
IgM ELISA, IgG 
ELISA,	real-time	 
RT-PCR;	limited 
virus isolation
Subset samples from 
classical CHIK cases, 
as determined by 
lab constraints and 
epidemiological status; 
Samples from all atypical 
or severe cases should 
be tested
Periodic outbreaks  
(once CHIKV has 
been detected in 
an area) or active 
surveillance in 
areas near CHIKV 
transmission
IgM ELISA, IgG 
ELISA,	real-time	 
RT-PCR;	limited	 
virus isolation
Subset of samples from 
classical CHIK cases, as 
determined by lab constraints 
and epidemiological status; 
samples from all atypical 
or severe cases should 
be tested
During the initial introduction of  CHIKV into a new region, comprehensive 
testing	should	be	completed	to	confirm	that	CHIKV	is	the	etiological	agent.	
After	CHIKV	has	been	identified,	limited	testing	(not	testing	all	specimens	or	
performing fewer assay types) can be considered depending upon the capacity 
of  the lab and the epidemiological situation.
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4C. interpretation and Reporting of Results
Figure 2 shows typical viremia and antibody response in humans and Table 6 
describes the typical results of  testing samples at various time points.
Figure 2. Viremia and immune response following
Chikungunya virus infection.
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Table	6.  Typical results of samples tested at various 
time points post-infection.
Days post illness 
onset
Virus testing Antibody testing
Day	1-3
RT-PCR	=	Positive
Isolation = Positive
IgM = Negative
PRNT = Negative
Day	4-8
RT-PCR	=	Positive
Isolation = Negative
IgM = Positive
PRNT = Negative
>Day  8
RT-PCR	=	Negative
Isolation = Negative
IgM = Positive
PRNT = Positive
The	following	laboratory	test	results	would	confirm	a	recent	CHIKV	infection:
•	 Isolation	of 	CHIKV,	including	confirmatory	identification	(either	IFA,	RT-
PCR, or sequencing).
•	 Detection of  CHIKV RNA by real time RT-PCR. 
•	 Identification	of 	a	positive	IgM	result	in	a	patient	with	acute	symptoms	of 	
CHIK,	followed	by	the	demonstration	of 	CHIKV-specific	antibody	deter-
mined by PRNT with viruses in the SFV serogroup.
•	 Demonstration of  seroconversion or a four-fold rise in PRNT, HI, or 
ELISA titers (again using other SFV serogroup viruses) between acute and 
convalescent specimens.
Autochthonous cases should be reported to WHO, in collaboration with an 
epidemiologist, according to International Health Regulations (IHR) (see section 6F).
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4d. Laboratory Network for diagnosing CHikv
Currently DVBD, CDC can provide diagnostic testing for CHIKV infection. 
Reagents and consultations can also be provided by CDC and the Public 
Health Agency of  Canada.  Depending on the availability of  resources and 
the epidemiologic situation, PAHO and CDC will be working together in the 
near future to improve CHIKV detection in the Region by providing training 
and reagents to existing dengue (RELDA) and other arbovirus laboratories in 
the Americas.  Furthermore, proficiency testing is planned to ensure testing 
quality in the Region. A contingency plan will be developed to ensure that all 
laboratories capable of  performing testing in the Americas have an adequate 
supply of  reagents and protocols.
Summary of Laboratory Section
•	 Both molecular and serologic techniques are available for the 
laboratory diagnostic evaluation of CHIKV infection.
•	 During an outbreak, laboratories will need to develop, with other 
public health partners, sample triage plans to avoid laboratory 
overload.
•	 Laboratories have a key role in the surveillance for CHIKV 
introduction and spread; ongoing training of laboratories for CHIK 
detection is needed throughout the Region.
•	 Collaboration is important, in order for network partner (public 
health) labs to be able to share materials.
•	 Reference	laboratories	in	the	Region	will	play	a	significant	role	
in	reagent	production	and	in	providing	laboratory	confirmation	
of suspected CHIK cases.
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5. CASE mANAgEmENT
5A. Treatment
There	is	no	specific	antiviral	drug	treatment	for	CHIK.	Symptomatic	treatment	is	
recommended after excluding more serious conditions like malaria, dengue, 
and bacterial infections.
Acute  D i sease
Treatment is symptomatic or supportive, comprised of  rest and the use of  
acetaminophen or paracetamol to relieve fever, and ibuprofen, naproxen, or 
another	non-steroidal	anti-inflammatory	agent	(NSAID)	to	relieve	the	arthritic	
component of  the disease. Using aspirin is not advised because of  the risk 
of  bleeding in small number of  patients and the risk of  developing Reye’s 
syndrome in children younger than 12 years of  age. In patients with severe joint 
pains that are not relieved by NSAID, narcotics (e.g., morphine) or short-term 
corticosteroids	can	be	used	after	evaluating	the	risk-benefit	of 	these	treatments.	
Patients	should	be	advised	to	drink	plenty	of 	fluids	to	replenish	fluid	lost	from	
sweating, vomiting, and other insensible losses. 
34
Subacute  and  Chron ic  D i sease
While recovery from CHIK is the expected outcome, convalescence can be 
prolonged (sometimes up to a year or even more) and persistent joint pain 
may	require	pain	management,	including	long-term	anti-inflammatory	therapy.	
Although an older study suggested that chloroquine phosphate offered some 
benefit,45 a recent double-blind, placebo-controlled randomized trial found it to be 
of  no real value treating joint symptoms.46 Disabling peripheral arthritis that has 
a tendency to persist for months, if  refractory to other agents, may occasionally 
respond to short-term corticosteroids.38 To limit the use of  oral corticosteroids, 
local injections (intra-articular) of  corticosteroids or topical NSAID therapy can 
be used. In patients with refractory joint symptoms, alternative therapies such 
as methotrexate can be evaluated. In addition to pharmacotherapy, cases that 
have	prolonged	 arthralgia	 and	 joint	 stiffness	may	benefit	 from	 a	program	of 	
graduated physiotherapy. Movement and mild exercise tend to improve morning 
stiffness and pain, but heavy exercise may exacerbate symptoms.
5B. Patient isolation Recommendations
To prevent the infection of  others in the household, the community, or the 
hospital, a patient with acute CHIK should avoid being bitten by Ae. aegypti or 
Ae. albopictus	mosquitoes	during	the	viremic	phase,	which	is	usually	the	first	week	
of  illness. As these mosquitoes bite during daytime, from dawn to dusk or even 
after	dark	in	the	presence	of 	artificial	light,	staying	under	an	insecticide-treated	
(IT) bednet or remaining in place with intact screens is highly recommended. 
Furthermore, physicians or health care workers who visit CHIK-infected 
patients at home should take care to avoid being bitten by mosquitoes by using 
insect repellent and wearing long sleeves and pants.
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One	hospital-associated	infection	of 	CHIK	has	been	identified	in	a	health-
care provider who had an accidental needle stick from a patient with CHIK.47 
Several laboratory workers also have contracted CHIKV infection after handling 
infected blood.48  These exposures indicate that direct contact transmission 
can occur. However, other modes of  transmission, such as through respiratory 
droplets or particles, have not been documented.
5C. Health Care and Hospital Surge Capacity
At	the	peak	of 	one	recent	outbreak,	47,000	suspected	cases	were	identified	in	a	
single week among a population of  766,000.27 There also can be an accumulation 
of  patients with symptoms who seek more long-term care. With that potential 
volume of  cases per week, huge demands are likely to be placed on the health 
care system during outbreaks of  the disease. A number of  steps similar to 
those	for	pandemic	influenza	preparedness	should	be	considered	by	health	care	
facilities preparing for and during a CHIK outbreak.  Triage systems should 
be	considered	at	various	levels	of 	health	care	to	facilitate	the	flow	of 	patients	
during an outbreak.
Prior to the introduction of  CHIKV, the following should be considered 
(adapted from PAHO and U. S. Department of  Health and Human Services 
(HHS)	Influenza	Pandemic	Plan49, 50):
•	 Develop and implement methods for identifying and investigating poten-
tial introduction of  CHIKV within existing surveillance systems (e.g., sur-
veillance system for dengue).
•	 Inform	health	care	providers	and	public	health	officials	about	the	potential	
threat of  CHIKV, and educate them about the clinical presentation, diag-
nosis, and management of  cases at health care facilities.
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•	 Develop planning and decision-making structures for responding to a po-
tential outbreak at health care facilities.
•	 Develop institutional plans to address disease surveillance, hospital com-
munications, education and training, triage and clinical evaluation, facility 
access, occupational health, surge capacity (beds and access to care), supply 
chain, and access to critical inventory needs. 
Following the introduction of  CHIKV into an area, health care facilities should:
•	 Activate institutional plans with assistance from the Ministry of  Health.
•	 Ensure rapid and frequent communication within health care facilities and 
between health care facilities and health departments.
•	 Implement	 surge-capacity	 plans	 that	 address	 staffing,	 bed	 capacity,	 con-
sumable and durable supplies, and continuation of  essential medical servic-
es (see section on Health care Planning in the PAHO and HHS Pandemic 
Influenza	Plan	for	further	considerations49, 50).
Effective triage systems at various levels of  health care may help to decrease the 
potential burden of  a CHIK outbreak on the health care system.  Regardless 
of  the level of  medical care available at the triage location, a key measure that 
needs to be considered at all levels of  health care is the institution of  appropriate 
mosquito control measures in the immediate area.  If  this is not done, patients 
acutely ill with CHIK can serve as a source of  subsequent infections for other 
patients and for health care workers via mosquito transmission.  Furthermore, 
consideration should be given to establishing areas where patients with suspected 
CHIK infection are seen and, if  necessary, hospitalized (e.g., establish CHIK 
wards with screens and/or bednets).  Finally, consideration should be given 
to the safety of  health care workers.  During a previous outbreak, up to one-third 
of  health care workers became infected, further taxing already overburdened and 
stretched resources.9  
‘Guiding principles for managing acute stage of  the disease’ has been previously 
described in detail in WHO’s “Guidelines on Clinical Management of  
Chikungunya Fever”. 51 Key information, including triage considerations, from 
that document is summarized here.
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Who should seek medical care?
•	 Anyone with neurologic signs or symptoms including irritability, drowsi-
ness, severe headaches, or photophobia.
•	 Anyone with chest pain, shortness of  breath, or persistent vomiting.
•	 Anyone with a fever persisting for more than five days (indicative of  
another illness like dengue).
•	 Anyone who develops any of  the following, especially once the fever subsides: 
- intractable severe pain,
- dizziness, extreme weakness, or irritability,
- cold extremities, cyanosis,
- decreased urine output, and
-	 any	bleeding	under	the	skin	or	through	any	orifice.
•	 Women in the last trimester of  pregnancy, newborns, and persons with 
chronic underlying disease, as they or their offsprings are at risk for more 
severe disease. 
Triage at point of first contact (Primary or ambulatory/urgent care)
•	 Rule out other illnesses by history, clinical examination, and basic labo-
ratory investigations, including but not limited to complete blood count 
(CBC), liver function tests, and electrolytes. Be careful to evaluate if  patient 
has warning signs for severe dengue or malaria. If  these signs are present, 
refer patient immediately to a hospital.
•	 Assess for dehydration and provide proper rehydration therapy as needed.
•	 Evaluate hemodynamic status and stabilize and immediately refer patients 
with	delayed	capillary	refill,	narrow	pulse	pressure,	hypotension,	oliguria,	
altered sensorium, or bleeding manifestations.  
•	 Treat symptomatically (paracetamol/acetaminophen).
•	 For those with prolonged joint pain (after three days of  symptomatic treat-
ment) consider more aggressive pain management, such as morphine and 
short-term corticosteroids.
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•	 Consider referral for patients with increased risk of  a poor outcome (persons 
older than 60 years, those with chronic disease, pregnant women, and newborns).
Triage at the secondary level (district or local hospital)
•	 Treat symptomatically (according to previous treatments).
•	 Investigate person for renal failure, neurologic signs and symptoms, he-
patic	insufficiency,	cardiac	illness,	thrombocytopenia,	and	malaria.	
•	 Evaluate hemodynamic status and assess for dehydration; provide proper 
supportive care and rehydration therapy as needed.
•	 Consider cerebral spinal tap if  meningitis is suspected.
•	 Collect blood for serologic testing of  CHIK and other diseases in the 
differential diagnosis (e.g., dengue).
•	 Review history of  present illness and evaluate if  patient has warning signs 
for severe dengue. If  present, administer supportive care in a unit that can 
monitor vital signs on an hourly basis during the critical phase. 
•	 Refer patients with any of  the following conditions to a higher level health 
center:	pregnancy,	oliguria/anuria,	refractory	hypotension,	significant	clini-
cal bleeding, altered sensorium, meningoencephalitis, persistent fever 
of  more than one week’s duration, and signs of  decompensation of  un-
derlying diseases.
Triage at the tertiary care level (advanced care centers or centers with 
infectious disease specialists)
•	 Ensure that all the above-mentioned procedures have been completed and 
that a comprehensive medical team is available to assist in managing pa-
tients with severe or atypical disease.
•	 Collect blood sample for serology and/or RT-PCR (see Laboratory section 
for	more	specific	on	CHIK	testing).
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•	 Consider the possibility of  other rheumatic (e.g., rheumatoid arthritis, 
gout, rheumatic fever) or infectious diseases (e.g., viral or bacterial menin-
goencephalitis).
•	 Treat serious complications (e.g., bleeding disorder with blood compo-
nents, acute renal failure with dialysis).
•	 Assess disability and recommend rehabilitative procedures.
•	 Given the severity of  the pain and the potential long-term pain with CHIK, 
pain management and psychological assistance should be made available 
and consideration given to develop chronic pain management protocols, 
teams, and centers. Autopsies should be considered on all deceased pa-
tients, with involvement of  pathologists.
5d. Blood, Organ, and Tissue Safety
Blood-borne transmission is possible. There are documented cases that include 
infection of  laboratory personnel handling infected blood and of  a health care 
worker drawing blood from an infected patient.47, 48  These cases support the 
belief  that CHIKV is able to be transmitted through blood products. 
To determine the impact of  CHIKV on blood supply safety consider: 1) incidence 
of  viremia among blood donors (which may vary depending on the time of  
the outbreak); 2) clinical impact on transfusion recipients who become infected; 
3) availability of  measures to reduce transfusion transmission (e.g., nucleic acid 
amplification	testing	(NAT)	or	photochemical	pathogen	inactivation	treatment);	
4) availability of  an alternative blood supply (from non-affected areas); and 5) 
the cost incurred by adopting these measures.52
CA
SE
m
AN
Ag
Em
EN
T
40
In addition to asking the local health-care community to promote optimal use 
of  blood components, possible considerations for blood safety in areas with 
CHIKV introduction could include:53
•	 Continue to obtain blood donations from local persons until an unaccept-
able incidence or prevalencea of  infection is reached in the community.
•	 Screen blood donors for symptoms prior to donation. 
•	 Asking donors to report any illness they experience after donating blood, 
while holding on to the blood donations for several days (e.g, 2-5 days) prior 
to releasing it.
•	 If  feasible, cease all blood donations in an area of  known CHIKV infec-
tions and import blood products from uninfected areas.
•	 Institute screening (e.g., NAT) of  the blood supply for CHIKV.  This will 
require a preexisting platform and regulatory clearance, and is unlikely to 
be available in most areas.
Similar measures should be considered for organ and tissue (grafts) transplantations.
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Summary of Case Management Section
•	 Treatment	for	CHIK	is	supportive,	using	anti-pyretics,	optimal	
analgesics,	and	fluids.
•	 Acutely infected patients need to be protected against mosquito 
bites to prevent further disease spread at home, in the community, 
and in the health care facility.
•	 Because CHIK will place a large burden on the community, 
including	on	all	levels	of	the	health	care	system,	well-established	
protocols and plans need to be developed in advance to assist 
in the triage, care, and rehabilitation of patients.
CA
SE
m
AN
Ag
Em
EN
T
42 43
42 43
6. SURvEiLLANCE ANd 
OUTBREAk RESPONSE
The main objective of  surveillance is to detect, in a timely manner, cases of  CHIK in the Americas. Early detection will allow for proper response	and	characterization	of 	the	outbreak	and	identification	of 	
the viral strains circulating.
6A. modes of Surveillance
Multiple modes of  surveillance can be considered to determine if  CHIK may 
have been introduced to an area, to track the disease once introduced, or to 
follow the disease once it has been established.
1 . Preparedness  phase
Reinforce existing febrile syndromic surveillance sentinel sites so they can detect 
CHIK cases. A percentage of  patients presenting with fever and arthralgia 
or fever and arthritis with no known etiology (e.g., negative test for malaria or 
dengue), should be tested for CHIK at the national reference laboratory (See 
Section 4 for more details on proposed laboratory surveillance testing). To 
ensure adequate laboratory testing and surveillance capacity, laboratories should 
be aware of  the laboratory network set up for testing and eventual distribution 
of  supplies.
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2 . Response  phase
Introduction
Once an autochthonous case of  CHIK is detected, an in-depth epidemiologic 
investigation must be conducted to:
•	 Track viral spread.
•	 Monitor for possible introduction into surrounding areas.
•	 Describe key epidemiologic and clinical features.
•	 Assess clinical severity and impact on society (e.g., days missed from work, 
school closures, etc.).
•	 Identify risk factors for infection or severe disease. 
•	 Identify circulating CHIKV lineages.
These efforts will be the basis for developing effective control measures.
Active, passive, and laboratory surveillance should be used to calculate and 
monitor indicators such as: incidence, rate of  spread, rate of  hospitalization 
(per infections), proportion of  severe disease, mortality ratios, and disability rates. 
Sustained transmission
Once	the	virus	has	been	identified	throughout	a	country,	scaling	back	of 	the	
level of  testing and active surveillance can be considered (e.g., testing only a 
fraction of  suspect cases or testing severe or atypical cases, newborns, cases 
identified	in	new	regions)	to	avoid	unnecessary	costs	in	resource-limited	settings.	
However, ongoing surveillance should be continued to monitor changes in the 
epidemiology and ecology of  CHIKV transmission. Any changes in surveillance 
at the national level should be readily communicated to other surveillance and 
prevention partners, such as vector control specialists, to ensure the quality and 
uniformity of  the data collected.
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6B. Case detection
Clinicians should consider CHIK in the differential diagnosis for individuals 
who are presenting with fever and arthralgias that are not explained by another 
etiology or have an atypical presentation, e.g., an atypical dengue presentation 
with more severe joint pain or conjunctivitis. The index of  suspicion should 
be heightened for a traveler or someone having contact with a traveler who 
has recently returned from an area with ongoing CHIKV infections (to obtain 
updated information on location of  CHIK outbreaks visit http://www.who.int/
csr/don/en/index.html or http://wwwnc.cdc.gov/travel/default.aspx).
Laboratory personnel should consider CHIK if  there is a low proportion 
of  samples that are seropositive for an etiology that has a similar clinical 
presentation,	like	dengue,	or	if 	there	are	a	number	of 	synovial	fluid	samples	
that are sterile on bacterial culture.  
Public health authorities should be alerted to small clusters of  disease (fever and 
arthralgia or arthritis) associated with a traveler returning from a CHIK endemic 
area or an increase in the number of  hospital visits for fever and arthralgia or 
arthritis occurring in a localized area in a short time.
6C. Case definition
Suspect case: a patient with acute onset of  fever >38.5ºC (101.3ºF) and severe 
arthralgia or arthritis not explained by other medical conditions, and who resides 
or has visited epidemic or endemic areas within two weeks prior to the onset of  
symptoms.
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Confirmed case:	a	suspect	case	with	any	of 	the	following	CHIK	specific	tests:
•	 Viral isolation.
•	 Detection of  viral RNA by RT-PCR.
•	 Detection of  IgM in a single serum sample (collected during acute or con-
valescent phase).
•	 Four-fold	increase	in	CHIKV-specific	antibody	titers	(samples	collected	at	
least two to three weeks apart).
During an epidemic, all patients need not be subjected to confirmatory tests as above. 
An epidemiologic link can be sufficient.
An	evaluation	of 	the	sensitivity	and	specificity	for	clinical	criteria	for	CHIKV	
infection was done during a large outbreak of  the disease.54  The combination of  
fever	and	polyarthralgias	had	the	best	sensitivity	and	specificity	at	84%	and	89%,	
respectively,	and	allowed	for	the	correct	classification	87%	of 	individuals	with	
serologically	confirmed	CHIKV	infection.
6d. Case Reporting
CHIK	is	not	a	notifiable	disease	in	most	countries.	However,	depending	on	
the epidemiologic situation, each country must determine independently when 
CHIK should be a disease of  mandatory reporting. Occurrence of  suspect 
cases could indicate a possible outbreak and, therefore, should be immediately 
reported to the nearest health authority in accordance with the IHR guidelines. 
Prior to the introduction of  CHIK into an area, clinicians should report any 
suspect or confirmed travel-related cases to local public health officials 
who, in turn, should report them to a regional level and then on to a national 
level, where the information should be summarized and shared with stakeholders 
(Figure 3).  In addition, other key partners, such as vector control management 
teams,	should	be	notified.
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Figure 3.  Scheme for notification of a suspected outbreak of CHIK.
6E. Epidemiologic Reports
Ideally, epidemiologic reporting should be established at the national level, with 
the	support	of 	local	and	regional	public	health	officials.	The	types	and	number	
of  epidemiologic reports will likely evolve during the course of  the outbreak to 
reflect	the	types	of 	surveillance	that	are	performed	in	an	area.
Following the introduction of  CHIK into an area, a line list of  suspect and 
laboratory confirmed cases should be kept and updated daily. Reporting 
should be coordinated at the national level by establishing a web-based line list, 
if  possible, that contains a few required variables and additional variables as 
needed.  A standardized case report form, including demographic, epidemiologic 
and laboratory information, should be developed quickly and shared with key 
partners to help facilitate the collection of  information (See Appendix D for 
an	example).		At	the	national	level,	there	should	be	clearly	defined	cutoffs	in	
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terms of  presenting and closing the data on a daily basis.  In addition to 
case count by location and timing, reporting on disease severity (hospitalization, 
mortality), number of  hospital beds occupied per day, and trends in cases based 
on syndromic surveillance can be considered as ways to present the data.  The 
national level data should be communicated back to the collecting districts, as 
well as to the press and other public health and partner agencies that participate 
in the control efforts (see Section 8, “Risk and Outbreak Communication” 
for	more	detail).		Once	a	country	has	identified	autochthonous	transmission	
within its borders, it should activate its emergency operations center (“sala de 
situación”) to serve as a source for rapid communication and decision making.
6F. international Health Regulations  
 and Border measures
In te rnat iona l  Hea l th  Regu la t ions
A single imported case (i.e., a traveler) of  CHIKV into the Americas would 
not necessarily constitute a public health emergency of  international concern 
(PHEIC) under IHR,55 although this case should be thoroughly investigated to 
minimize the risk of  CHIK establishment in the country.  However, suspicion of  
autochthonous CHIKV transmission in the Americas will meet PHEIC criteria 
and should be reported per IHR (see Appendix E for an example).  Such an 
event would have a serious public health impact because of  its potential to cause 
an epidemic with high attack rates among an immunologically naïve population, 
and	because	vectors	are	sufficiently	abundant	to	potentially	support	permanent	
establishment of  the virus and year-round transmission. The event would also 
be unusual for the Americas, since it would signal the appearance of  a previously 
absent	pathogen	and	a	significant	risk	of 	international	spread	given	the	amount	
of  travel between countries in the Region.  Although CHIKV does not have a high 
mortality rate, it has high morbidity rates associated with persistent arthralgias 
that can lead to disability and a reduction in productivity. The establishment of  
CHIKV in a Member Country could also affect key national income sources, 
such as tourism. For example, La Réunion Island observed a 60% decline in 
tourism after its CHIKV outbreak.56
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Any Member Country should thoroughly investigate any suspect CHIK case 
detected without a travel epidemiologic link to another country and rule out 
indigenous CHIKV transmission. PAHO recommends that Member Countries 
consider making the reporting of  CHIK mandatory to enable and promote a 
timely response.  
Border  Measures
Closing borders due to suspected CHIKV cases would be counterproductive 
and it is not recommended by WHO. It also is inconsistent with the IHR, which 
emphasize detection and containment at the new source of  transmission, rather 
than control at borders of  entry.  The costs associated with screening for CHIK 
at	ports	of 	entry	outweigh	the	benefits.		It	is	insufficiently	sensitive	and	specific	
and too expensive to be a tool for preventing CHIKV introduction and spread. 
The anticipated prevalence among travelers coming from areas of  the world with 
CHIKV	activity	is	low,	symptoms	are	non-specific,	and	screening	would	yield	a	
low positive predictive value. The reported experience of  entry screening for 
CHIKV in Taiwan validates this point.  During 2006, more than 11.7 million 
passengers	arrived	 in	Taiwan.	Of 	these	passengers,	6,084	were	 identified	as	
having fever using thermal infrared imaging cameras; laboratory testing of  
passengers detected 44 cases of  dengue fever, 13 cases of  shigellosis, 1 case of  
malaria, 1 case of  paratyphoid fever, and 1 case of  CHIK (JW Hsieh, Centers 
for Disease Control, Ministry of  Health, Taiwan,personal communication, 2007).
Even disregarding the issue of  cost and complexity of  implementation, port of  
entry screening activities are unlikely to prevent or delay the importation of  CHIKV. 
There is no evidence to support that requiring pilots or ship captains to complete 
health declarations, asking passengers to complete screening questionnaires, taking 
temperature measurements and engaging in other entry screening modalities 
effectively prevent CHIKV introduction and spread into the Americas. Member 
Countries should use their scarce public health resources on activities more likely 
to achieve intended results, including implementing sustainable vector control 
efforts, enhancing clinical surveillance for CHIKV disease, educating the public, 
and considering assisting affected Member Countries.  For similar reasons, exit 
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screening is not recommended if  Member Countries in the Americas confront 
CHIKV outbreaks within their borders.
Some jurisdictions outside the Americas have instituted mosquito abatement 
activities at international airports and spraying adulticides in the passenger 
cabins	of 	arriving	international	flights	as	part	of 	efforts	aimed	at	preventing	
dengue importation.  However, virus-infected mosquitoes arriving in passenger 
aircraft	are	not	considered	as	significant	sources	of 	most	arboviral	importations.	
For arboviruses with a human-mosquito-human transmission cycle, the most 
important source of  viral importation is the viremic traveler.  In a region like 
the Americas, where competent vectors are already present in the majority of  
countries, mosquito abatement and vector surveillance efforts predominantly 
focused on international airports and seaports can be implemented by national 
authorities to prevent CHIKV importation, but PAHO does not recommend them. 
The exception would be if  cases were being detected close to an international 
airport or seaport, or if  suspected cases worked in or around these ports of  entry. 
Routine vector control efforts consistent with IHR Article 22, which calls for 
eliminating vectors at facilities used by travelers at points of  entry, should be 
implemented, but are not intended as a principal means of  preventing CHIKV 
importation.
Similarly, in the presence of  CHIK cases and local virus transmission, there 
is no need to place any restrictions on baggage, cargo, containers, goods, or 
postal parcels beyond usual practices; this will avoid unnecessary interference 
with	international	traffic	in	the	absence	of 	any	identified	public	health	benefit.	
It is advisable, however, to establish communications between public health 
authorities and conveyance operators (sea and air, cargo and passenger) and 
other port-based organizations, in case there is a need to implement a CHIKV 
communication campaign.
Countries may elect to distribute Travel Health Alert Notices (THANs) to 
international travelers if  there is concern that CHIKV transmission is likely or if  
ongoing transmission has been detected.  This information would offer guidance 
to travelers on how to reduce their risk of  contracting CHIKV, steps to take for 
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reducing the likelihood that they will be bitten by mosquitoes, or seeking early 
diagnosis if  they develop signs and symptoms compatible with CHIK fever. 
These messages could be relayed through online reservation systems, travelers’ 
health clinics, travelers’ health Web sites, and postings at international ports 
when outbreaks are occurring.  
It will be important to monitor air travel patterns between countries where 
CHIKV is circulating and every other country or area in the Americas, in order 
to identify locations most at risk to virus introduction.  In a preliminary analysis 
that	was	limited	exclusively	to	direct	flight	data,	scheduled	commercial	flight	
data shows that countries importing CHIKV had 23 times more total scheduled 
passenger seats originating from countries with CHIKV activity than did non-
importing countries (CDC, unpublished).  Subsequent analyses using passenger-
specific	data,	which	includes	travel	connections	and	actual	passenger	volume,	
could provide more accurate information on which to base a risk assessment of  
CHIKV importation.
Summary of Surveillance and Outbreak 
Response Section
•	 Epidemiological surveillance is key to the timely detection of cases 
and appropriate and rapid response with active participation from 
all stakeholders.
•	 CHIK surveillance should be built upon existing dengue surveillance 
(highlighting differences in clinical presentation).
•	 If	autochthonous	transmission	of	CHIK	is	identified,	it	must	be	
reported immediately as a PHEIC under IHR.  
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7. vECTOR SURvEiLLANCE 
ANd CONTROL
In the absence of  an effective CHIKV vaccine, the only tool available to prevent infection is reduction of  human-vector contact. The primary vectors of  CHIKV are Ae. aegypti and Ae. albopictus.  Ae. aegypti is the principal 
vector in areas of  Africa where the virus is considered to be endemic.  However, 
Ae. albopictus was incriminated during recent epidemics, following introduction 
of  the virus into temperate Europe17 and some tropical areas of  the Indian 
Ocean.27, 57  These outbreaks were associated with an adaptation of  CHIKV 
strains to Ae. albopictus.58, 59  Both Ae. aegypti and Ae. albopictus are present in 
the Americas (Figures 4 and 5).  Ae. aegypti will likely be the most important 
vector in urban areas, and Ae. albopictus	will	likely	play	a	more	significant	role	in	
temperate areas and areas where it is already well established. Both mosquitoes 
could support the introduction of  CHIKV strains into a variety of  geographic 
areas in the Region. Therefore, vector control planning efforts should focus on 
suppression of  both Ae. aegypti and Ae. albopictus populations to prevent the 
likelihood of  CHIKV establishment and to lay the foundation for emergency 
interventions in the event of  an outbreak.
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Figure	4.		Distribution of Ae. aegypti in the Americas.a 
a  Adapted	from	Arias,	2002.60
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Figure	5.		Approximate distribution of Ae. albopictus in the Americas.a
a Adapted	from	Benedict	et	al.	2007.61
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There	are	some	significant	differences	between	Ae. aegypti and Ae. albopictus 
that must be considered in developing surveillance and control procedures. 
Ae. aegypti is more closely associated with humans and their homes, and feeds 
preferentially on humans.  Adult Ae. aegypti rest indoors, and its larval habitats 
are most frequently containers on the household premises.  Ae. albopictus feeds 
readily on humans, but also utilizes a broader range of  bloodmeal hosts;62 its 
larvae occur in peridomestic habitats as well as surrounding natural habitats. 
Ae. albopictus can overwinter in the egg stage and, therefore, can occupy more 
temperate climates63 than Ae. aegypti.  These species have distinct morphological 
features,	and	the	identification	of 	specimens	collected	during	surveillance	and	
control programs in the Americas can be readily accomplished.64, 65
An effective, operational dengue control program provides the basis for CHIKV 
preparedness, because the biology and control procedures for Ae. aegypti are 
similar to those for Ae. albopictus. Surveillance and control recommendations 
developed for dengue management66 as a component of  the Integrated 
Management Strategy for Dengue Prevention and Control (IMS-Dengue) may 
be utilized and intensified in order to respond to a CHIKV introduction. 
Successful control programs require well trained professional and technical staff  
and	sufficient	funding.		In	addition,	an	independent	quality	assurance	program	
should be incorporated into the integrated vector management (IVM) scheme.
To be successful, the CHIKV IVM program must include intersectoral 
participation (collaboration) at all levels of  government and among health, 
education, environment, social development, and tourism agencies. IVM 
programs	also	benefit	from	participation	of 	non-governmental	organizations	
(NGOs) and private organizations. CHIKV control program must communicate 
with and mobilize the entire community.67  In fact, the community’s participation 
is an essential component of  IVM.68  To be effective, an IVM strategy must be 
developed and in place before CHIKV is introduced.  
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7A. Reducing the Risk of CHikv
Components of  an IVM program to reduce CHIKV risk include:
1. Vector Surveillance and Identification of High Risk Areas
In areas where dengue is endemic, a retrospective analysis of  Dengue virus 
transmission during previous years should be conducted during the CHIKV 
planning phase to indicate the areas where CHIKV is expected to circulate (given 
the	similarity	in	transmission	cycles	of 	these	viruses).		Areas	can	be	stratified	in	
terms of  risk of  transmission.69		Stratification	is	then	used	to	assign	resources	
and priorities.  For example, controlling or preventing CHIKV transmission in 
neighborhoods that traditionally have produced many cases of  dengue should 
inhibit	virus	amplification	and	virus	spread	to	nearby	neighborhoods.
The program must have the ability to systematically collect surveillance data 
on relative densities of  Ae. aegypti and Ae. albopictus.  Surveillance methods for 
Ae. aegypti and Ae. albopictus are varied and include methods to monitor egg 
production, larval sites, pupal abundance, and adult abundance. These methods 
are reviewed in Chapter 5 of  the WHO Dengue Guidelines.66  New traps 
and sampling methods are being developed that may provide more accurate 
surveillance data.70, 71 Programs must be able to detect and identify hidden and 
difficult	to	control	larval	sites	(e.g.,	cryptic	locations	such	as	septic	tanks,	storm	
drains, sump pumps, and vacant lots) and other productive sites, as well as the 
readily	identified	and	commonly	found	larval	habitats.				
2. Personal Protection
Individuals may reduce the likelihood of  infection by the use of  personal 
repellents on skin or clothing.  DEET (N,N-diethyl-m-toluamide) and picaridin 
(also known as KBR3023 or Bayrepel™) are effective repellents widely available 
in the Americas. Infants and others sleeping or resting during the day should use 
bednets to avoid infection from Ae. aegypti and Ae. albopictus, both of  which are 
day biting mosquitoes. It is of  particular importance that individuals who are 
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potentially infected with CHIKV during an outbreak rest beneath an IT bednet 
to avoid mosquito bites and further spread of  infection.  Use of  IT bednets 
has	the	additional	benefit	of 	killing	mosquitoes	that	come	into	contact	with	the	
net, which may reduce vector-human contact for other household members.72 A 
number of  pesticide products may be used to safely treat bednets (Table 6), or 
long-lasting pretreated nets can be obtained commercially.
 
Table	6.		WHO recommended insecticide products for treatment
of mosquito nets.a 
1.  Conventional treatment:
Insecticide Formulationb Dosagec
Alpha-cypermethrin SC	10% 20−40
Cyfluthrin EW	5% 50
Deltamethrin
SC	1%;	WT	25%;	and	
WT	25%	+	Binderd
15−25
Etofenprox EW	10% 200
Lambda-cyhalothrin CS	2.5% 10−15
Permethrin EC	10% 200−500
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2.  Long-lasting treatment:
Product name Product type
Status of WHO 
recommendation
ICON® MAXX
Lambda-cyhalothrin	
10%	CS	+	Binder
Target dose  
of	50	mg/m2
Interim
aAdapted	from	http://www.who.int/whopes/Insecticides_ITN_Malaria_ok3.pdf
bEC	 =	 emulsifiable	 concentrate;	 EW	 =	 emulsion,	 oil	 in	 water;	 CS	 =	 capsule	
suspension; SC= suspension concentrate; WT = water dispersible tablet 
cMilligrams of active ingredient per square meter of netting. 
dK-O	TAB	1-2-3
3. Household Prevention
The use of  intact screens on windows and doors will reduce entry of  vectors into 
the	home,	and	mosquito	proofing	water	storage	vessels	will	reduce	oviposition	
sites and local production. Within a household, use of  IT bednets72 and IT 
curtains73 also reduce vector-human contact.
The number of  adult mosquitoes in a home may be reduced by using commercially 
available pyrethroid-based aerosol sprays and other products designed for the 
home, such as mosquito coils and electronic mat vaporizers. Aerosol sprays 
may be applied throughout the home, but areas where adult mosquitoes 
rest (dark, cooler areas) must be targeted, including bedrooms, closets, clothing 
hampers, etc.  Care should be taken to emphasize proper use of  these products 
when advocating their application to the public, in order to reduce unnecessary 
exposure to pesticides.
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4. Neighborhood and Community Prevention 
Neighborhood and community prevention for a CHIKV introduction in 
the Americas should be based on methods developed for dengue control, 
utilizing effective strategies to reduce the densities of  vector mosquitoes.66 A 
fully operational dengue control program will reduce the probability that a 
viremic human arriving in the Americas will be fed upon by Ae. aegypti or Ae. 
albopictus mosquitoes, thereby leading to secondary transmission and potential 
establishment of  the virus.
Dengue programs for controlling Ae. aegypti have traditionally focused on 
control of  immature mosquitoes, often through the community’s involvement in 
environmental management and source reduction. It is essential that community 
involvement be incorporated into an IVM program.74, 75  
Vector  Cont ro l  Procedures
The WHO Dengue Guidelines66 provide information on the main methods of  
vector control, and they should be consulted when establishing or improving 
existing programs. The program should be managed by experienced professional 
vector control biologists to assure that the program uses current pesticide 
recommendations, incorporates new methods of  vector control, and includes 
resistance testing.  Prevention programs should utilize the methods of  vector 
control found in Appendix F, as appropriate.66, 74
7B. Response to CHikv introduction
Immediately	upon	confirmation	of 	the	first	autochthonous	CHIKV	case,	the	
health department should inform the IVM program regarding the onset date and 
location	of 	the	case.	Vector	control	procedures	must	be	intensified	to	effectively	
reduce the abundance of  infected vectors in order to halt transmission in the 
areas of  the case(s).  
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Simultaneously, emergency response committees at local and national levels 
should be informed of  the situation and activated.  Initial efforts should focus 
on containing virus transmission and preventing expansion (Appendix G). If  
virus containment fails, or if  cases are not detected until the outbreak has spread 
over a large geographic area, intensive vector control efforts will need to be 
expanded to a larger scale program.
Summary of Vector Surveillance and Control Section
•	 Epidemiological surveillance is key to the timely detection of 
cases Early detection of disease will increase the likelihood of 
containing transmission of CHIKV in the area.
•	 Successful IVM for CHIKV requires trained experts in medical 
entomology and vector control, sufficient resources, and a 
sustained commitment.
•	 Current dengue control programs in the Region should be utilized 
and improved to prevent CHIKV transmission.
•	 Vector surveillance and control activities and methodologies 
must	be	validated	and	continually	evaluated	to	measure	efficacy.
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8. RiSk ANd OUTBREAk 
COmmUNiCATiON
8A. Risk Communication for CHikv introduction 
or Outbreaks
Effective communication to the community and various stakeholders is crucial to 
avoid confusion and misinformation and to engage people in steps to reduce the 
risk of  disease. Under IHR, risk communication for public health emergencies 
includes the range of  communication capabilities through the preparedness, 
response, and recovery phases of  an outbreak.55 Messages should encourage 
informed decision making, positive behavior change, and the maintenance 
of  trust in public authorities. As CHIKV is new to the Americas, the media, 
the	public,	and	many	officials	will	need	to	be	educated	about	the	disease,	its	
mode	of 	 transmission,	 the	 lack	of 	 specific	 therapeutic	 treatment,	means	of 	
symptomatic and supportive treatment, and the adoption of  control measures. 
Risk communication messaging can emphasize that the risk of  CHIKV infection 
can be reduced, and that it is typically a self-limiting disease.
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8B. Risk Communication Strategies by  
Phase and Target Audience
Appendix H gives an example of  a model risk communication plan with strategies 
organized by preparedness, response, and recovery phases of  an emergency. The 
plan	defines	various	target	audiences	that	should	be	considered	in	developing	a	
country-specific	risk	communication	plan.
Risk communication should be organized across multiple agencies and should target 
the media, the public health community, community-based organizations, the private 
sector, and civil society institutions.  
Structure  and  Coord inat ion
Ideally, an emergency response to a CHIKV outbreak will use an Incident 
Command System that provides structure for collaboration. In Latin America, 
the equivalent is the Emergency Operational Committee (or COE in Spanish). 
A key component in emergency operations is the establishment of  a Joint 
Information Center (JIC) that allows for coordination of  messages from local, 
state, national, and international partners. Information about setting up and 
running a JIC can be found online at: http://www.fema.gov/emergency/
nims/PublicInformation.shtm
As part of  the emergency operations structure, communication staff  should 
work closely with other operational components (epidemiology, vector control, 
etc.). All groups should meet regularly ensure that they are in agreement on 
key data points, including number of  cases, geographic factors, and messages. 
Lack of  coordination on these points will help create confusion and undermine 
confidence	in	the	management	of 	the	response.
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Stra tegies  by  Phase : Preparedness  Phase
The primary activities during the preparedness phase are to develop a 
communications plan and to create strategic partnerships. During this phase, 
potential activities may include:
•	 Informing key stakeholders about preparedness materials, such as these 
guidelines.
•	 Developing basic response materials, such as fact sheets and frequently asked 
questions, will facilitate a rapid response to a CHIKV introduction and 
reduce misinformation. Information channels may include printed materi-
als, websites and other electronic and social media, the mass media, short 
message service (SMS) text messages, inter-personal communication through 
group meetings, schools, and utilization of  traditional or folk media.
•	 Working with partners to develop strategies to guide care seeking, travel 
(national and international), and prevention/risk reduction. 
•	 Communication with journalists and news agencies to provide baseline in-
formation on CHIKV and on the national preparedness and response plan. 
•	 Networking with key personnel at potential information points, such as 
arrivals and departure locations (airports, ports, borders) and public facil-
ities (health care facilities, educational centers, workplaces, nursing homes, 
shopping malls, churches, public transport sites, stadiums, among others).
•	 Anticipating sensitive issues can allow for preemptive preparation of  re-
sponses and strategies. Sensitive topics related to CHIKV may include 
concern over safety of  community and household pesticide use, any 
restrictions involved in a containment response, large numbers of  persons 
seeking care at health care facilities, and the cost of  control measures.  
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Stra tegies  by  Phase : The  Response  Phase 
During the response phase, the communication plan is put into action; in 
particular, communications with the mass media, health care providers, and other 
key	audiences	are	intensified.	
The Mass Media
Effective communication through the mass media can help maintain clear 
information regarding the outbreak and the public health response. Information 
should be communicated via an appropriate, trained national-level spokesperson. 
Use of  a consistent spokesperson can build trust and avoid the release of  
potentially	conflicting	messages	from	various	sources.	Information	in	the	mass	
media can also reinforce the key behavioral outcomes that can help reduce risk 
during an outbreak. Content in the electronic and print media should be regularly 
monitored (on a daily basis during an intense outbreak), in order to make any 
necessary adjustments to the strategies and messages conveyed to the population.
Response to media inquiries should be timely and accurate, and should include 
promotion and prevention issues. Messaging for media responses should 
be coordinated through the JIC. Sensitive issues should be addressed promptly 
and transparently, following best crisis and risk communication principles: 
http://www.bt.cdc.gov/cerc/ 
It is useful to employ multiple channels to disseminate accurate information 
on the disease and its prevention. These may include advertising and other social 
marketing tools (e.g., TV, radio, printed media, the Web, outdoor billboards, and 
social networks, such as Twitter, Facebook, or YouTube). Relying on multiple 
channels may be especially important when the outbreak engenders confusion 
and controversy.  
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Health Care Provider Communication
Because CHIKV is a new disease in the Region, many health care providers 
probably	will	have	little	specific	information	available	on	diagnosis	and	care	
for CHIK patients.  Mechanisms for rapid communication with care providers 
should be established, such as dedicated health care provider websites, health alert 
network notices, and communication via professional associations.  Ideally, basic 
materials	can	be	prepared	in	advance	of 	an	outbreak.		Specific	communication	
strategies should reflect the actual availability of  electronic media to health 
care providers throughout the Region. See Appendix H for further details.
Stra tegies  by  Phase : The  Recovery  Phase 
During the recovery phase, the main activities include guiding the general 
population on the sustainment of  appropriate public health measures, and 
informing the public when the risk of  disease transmission has been reduced. At 
this point there also is an opportunity to evaluate and assess the effectiveness of  
risk communication efforts.  A summary evaluation at the end of  the outbreak 
will provide valuable insight for future responses. For further details refer to 
Appendix H.  
8C. Specific Behavioral Strategies 
for CHikv Risk Reduction 
Specific	strategies	for	effective	personal,	household,	and	community	primary	
prevention are discussed in section 7 (Vector Surveillance and Control). Messages 
regarding control measures should be developed in collaboration with vector 
control	staff,	and	should	emphasize	specific	steps	that	households	must	consider	
to optimize potential control measures (e.g., leaving windows open during 
fogging, which materials to remove from the home in the event of  indoor residual 
application, what the larvicide looks like and how long to leave in place, etc.).
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Advance research into knowledge, attitudes, and practices regarding repellent 
and	household	control	measures	may	yield	benefits	in	understanding	barriers	
to use and potential for misapplication. Even if  it is not feasible to conduct 
this research in advance, rapid qualitative assessment in affected areas can 
yield insights to increase the effectiveness of  prevention messages. 
Communication on prevention should target specific behaviors that offer 
the best likelihood of  reducing risk. Feasible strategies will vary by location, 
depending on a given community’s resources, attitudes, control program capacity, 
and ecology.  Key messages for personal and household prevention can include:
Communi ty  St ra tegies 
•	 Encouraging support of  and compliance with governmental control ef-
forts such as environmental sanitation, larviciding and adulticiding.
•	 Advocacy for household and neighborhood source reduction (e.g., trash 
clean-up, control of  water storage, etc.).
Househo ld  and  Persona l  S t ra tegies 
•	 Use of  personal prevention such as clothing, repellents, and insecticide-
treated materials: 
- Encouraging the use of  long sleeves and pants may be reasonable in areas 
where temperatures are moderate, particularly during evening when Aedes 
mosquitoes are often still seeking a bloodmeal. This recommendation may 
be less practical in tropical zones.
- Repellents for use on skin and clothing are now sold widely throughout 
the	Americas.	A	significant	outbreak	may	increase	interest	in	these	tools,	
and authorities should be prepared to provide guidance and to rely on 
creative strategies to increase use.  
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•	 Methods to reduce human-vector contact include use of  household in-
secticides and installation of  screening. Where feasible, screening materi-
al can be installed over windows even without the use of  expensive frames 
(stapling in place or using wooden frames). 
•	 It may be useful to specify active ingredients or even brand names for rec-
ommended repellent and/or household insecticides, as a way to reduce 
use of  ineffective and possibly dangerous materials.
Summary of Risk and Outbreak  
Communication Section
•	 Communications are an integrated, coordinated effort involving 
all disciplines and components for preparation and response.
•	 Timely communication with stakeholders is crucial for enlisting 
the community’s participation and to avoid confusion and 
misinformation.
•	 As CHIKV is novel in the Americas, the media, the public and 
many officials will need to be educated about the disease, the 
mode	of	transmission,	the	lack	of	specific	therapeutic	treatment,	
means of symptomatic and supportive treatment, and effective 
control measures. 
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9. CONCLUSiON
Currently, CHIKV is not known to be circulating in the Americas. The risk of  introduction is high, however, due to travel importation, competent vectors (same vectors as dengue), and population susceptibility.  Given 
the likelihood that CHIKV will be introduced in the Region, advance preparation 
is essential. The timely detection of  cases and an appropriate and rapid response 
with active participation of  all stakeholders will be necessary to minimize the risk 
of  importation and sustained transmission in the Region.
These guidelines for the preparedness and response CHIKV introduction in the 
Americas were developed to increase awareness of  the disease and to provide 
the necessary information to institute the most appropriate strategies to prevent 
the importation and spread of  CHIKV in the Region.  Each Member Country 
is encouraged to use and adapt these guidelines to detect an outbreak of  the 
disease early, to conduct pertinent epidemiologic investigations, and to prevent 
or mitigate the expansion of  the disease in the Americas.
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	s
po
t	s
lid
es
	a
re
	p
re
pa
re
d	
fo
r	
IF
A
	e
xa
m
in
at
io
n	
us
in
g	
m
on
oc
lo
na
l	d
en
gu
e	
ty
pe
-s
pe
ci
fic
	a
nt
ib
od
ie
s.
	
C
on
tr
ol
s 
U
ni
no
cu
la
te
d	
Ve
ro
	a
nd
	C
6/
36
	c
el
ls
In
te
rp
re
ta
tio
n 
P
os
iti
ve
	v
iru
s	
is
ol
at
io
n,
	re
is
ol
at
io
n,
	a
nd
	d
efi
ni
tiv
e	
id
en
tifi
ca
tio
n	
de
fin
e	
th
e	
et
io
lo
gi
c	
ag
en
t	o
f	t
he
	p
at
ie
nt
’s
	il
ln
es
s.
		
If	
pa
ire
d	
se
ra
	o
r	a
	c
on
va
le
sc
en
t	s
er
um
	fr
om
	th
at
	p
at
ie
nt
	a
re
	a
va
ila
bl
e,
	th
e	
id
en
tifi
ed
	v
ira
l	i
so
la
te
	is
	te
st
ed
	
se
ro
lo
gi
ca
lly
 w
ith
 t
he
 p
at
ie
nt
’s
 s
er
a 
to
 v
er
ify
 a
nt
ib
od
y 
re
sp
on
se
 t
o 
th
at
 v
iru
s.
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gr
ap
hy
•	
Ts
ai
,	T
H
:	A
rb
ov
iru
se
s,
	p
.6
06
-6
18
.	I
n	
R
os
e	
N
R
,	d
e	
M
ar
ca
rio
	E
C
,	F
ah
ey
	J
L,
	F
rie
dm
an
	H
,	a
nd
	P
en
n	
G
M
	(e
ds
):	
M
an
ua
l	o
f	C
lin
ic
al
	L
ab
or
at
or
y	
Im
m
un
ol
og
y,
	4
th
	e
d.
	A
m
er
ic
an
	S
oc
ie
ty
	fo
r	M
ic
ro
bi
ol
og
y,
	W
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hi
ng
to
n,
	D
C
,	
19
92
.	
•	
K
ar
ab
at
so
s	
N
:	A
rb
ov
iru
se
s.
	C
ha
p.
	2
7.
	In
	H
si
un
g	
G
D
,	F
on
g	
C
,	L
an
dr
y	
M
	(e
ds
):	
D
ia
gn
os
tic
	v
iro
lo
gy
,	4
th
	e
d,
	
Ya
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	U
ni
ve
rs
ity
	P
re
ss
,	N
ew
	H
av
en
,	C
T,
	1
99
3.
•	
S
ch
m
id
t	N
J:
	C
el
l	c
ul
tu
re
	te
ch
ni
qu
es
	fo
r	d
ia
gn
os
tic
	v
iro
lo
gy
.	I
n	
Le
nn
et
te
	E
H
,	S
ch
m
id
t	N
J	
(e
ds
):	
D
ia
gn
os
tic
	
pr
oc
ed
ur
es
	fo
r	v
ira
l,	
ric
ke
tt
si
al
,	a
nd
	c
hl
am
yd
ia
l	i
nf
ec
tio
ns
,	5
th
	e
d,
	A
m
er
ic
an
	P
ub
lic
	H
ea
lth
	A
ss
oc
ia
tio
n,
	
W
as
hi
ng
to
n,
	D
C
	1
97
9.
•	
B
ea
ty
	B
J,
	C
al
is
he
r	C
H
,	a
nd
	S
ho
pe
	R
S
:		
A
rb
ov
iru
se
s,
	p
.	7
97
-8
56
.	I
n	
S
ch
m
id
t	N
J,
	E
m
m
on
s	
R
W
	(e
ds
):	
D
ia
gn
os
tic
	p
ro
ce
du
re
s	
fo
r	v
ira
l,	
ric
ke
tt
si
al
	a
nd
	c
hl
am
yd
ia
l	i
nf
ec
tio
ns
,	6
th
	e
d,
	A
m
er
ic
an
	P
ub
lic
	H
ea
lth
	
A
ss
oc
ia
tio
n,
	W
as
hi
ng
to
n,
	D
C
,	1
98
9.
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A
pp
en
di
x 
B
. R
ea
l-
T
im
e 
R
ev
er
se
 T
ra
ns
cr
ip
ta
se
-P
ol
ym
er
as
e 
C
ha
in
 R
ea
ct
io
n 
P
ro
to
co
l
R
ea
l	t
im
e	
R
T-
P
C
R
	c
an
	b
e	
pe
rf
or
m
ed
	u
si
ng
	a
	n
um
be
r	o
f	c
om
m
er
ci
al
ly
	a
va
ila
bl
e	
ki
ts
.		
Ei
th
er
	th
e	
B
io
R
ad
	iS
cr
ip
t	1
	S
te
p	
R
T-
qP
C
R
	(#
17
0-
88
95
)	o
r	t
he
	Q
IA
G
EN
	Q
ua
nt
iT
ec
t	P
ro
be
	R
T-
P
C
R
	k
it	
(#
20
44
43
)	i
s	
cu
rr
en
tly
	u
se
d	
by
	th
e	
A
rb
ov
ira
l	D
ia
gn
os
tic
	L
ab
or
at
or
y	
at
	D
VB
D
,	C
D
C
.		
Th
e	
tw
o	
ki
ts
	a
re
	n
ea
rly
	id
en
tic
al
	in
	th
e	
re
ac
tio
n	
se
tu
p,
	w
ith
	o
ne
	e
xc
ep
tio
n:
	th
e	
vo
lu
m
e	
of
	e
nz
ym
e	
us
ed
	in
	th
e	
Q
IA
G
EN
	k
it	
is
	0
.5
	µ
l	p
er
	
re
ac
tio
n,
	in
st
ea
d	
of
	1
.0
	µ
l;	
th
e	
vo
lu
m
e	
of
	w
at
er
	in
	th
e	
m
as
te
r	
m
ix
	is
	a
dj
us
te
d	
by
	0
.5
	µ
l	t
o	
ac
co
un
t	f
or
	th
is
.	T
he
	s
et
up
	s
ho
w
n	
be
lo
w
	is
	
fo
r	t
he
	Q
IA
G
EN
	k
it.
		N
ot
e	
al
so
	th
at
	th
e	
vo
lu
m
e	
of
	R
N
A
	a
dd
ed
	p
er
	re
ac
tio
n	
be
lo
w
	is
	1
0	
µl
	b
ut
	c
an
	b
e	
in
cr
ea
se
d	
or
	d
ec
re
as
ed
	w
ith
	th
e	
ap
p
ro
p
ria
te
 a
d
ju
st
m
en
t 
of
 t
ot
al
 v
ol
um
e 
w
ith
 w
at
er
.
C
om
p
on
en
t
Vo
l. 
p
er
 r
ea
ct
io
n
10
	R
ea
ct
io
ns
R
N
as
e 
fr
ee
  w
at
er
13
.2
	µ
l
13
2	
µl
2X
  R
ea
d
y 
m
ix
25
	µ
l
25
0	
µl
pr
im
er
	1
	(1
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	µ
M
	s
to
ck
)
0.
5	
µl
	
5	
µl
pr
im
er
	2
	(1
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	µ
M
	s
to
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)
0.
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0.
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FA
M
/	p
ro
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	(2
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	s
to
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)
0.
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	µ
l
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µl
en
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m
e
0.
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P
re
p
ar
e 
a 
re
ag
en
t “
m
as
te
r 
m
ix
” 
ac
co
rd
in
g 
to
 th
e 
nu
m
b
er
 o
f r
ea
ct
io
ns
 d
es
ire
d
.  
Th
e 
m
as
te
r 
m
ix
 s
ho
ul
d
 b
e 
p
re
p
ar
ed
 in
 a
 “
cl
ea
n 
ro
om
” 
th
at
 is
 p
hy
si
ca
lly
 s
ep
ar
at
ed
 f
ro
m
 a
ll 
ot
he
r 
la
b
or
at
or
y 
ac
tiv
iti
es
 a
nd
 t
ha
t 
ha
s 
d
ed
ic
at
ed
 r
ea
ge
nt
s 
an
d
 e
q
ui
p
m
en
t 
(e
.g
., 
p
ip
et
te
s)
. 
 F
or
 
10
	s
am
pl
es
	m
ak
e	
a	
10
X	
m
as
te
r	
m
ix
	(s
ee
	a
bo
ve
)	b
y	
m
ul
tip
ly
in
g	
th
e	
vo
lu
m
es
	o
f	a
ll	
in
di
vi
du
al
	r
ea
ge
nt
s	
by
	1
0.
		
C
om
bi
ne
	t
he
	r
ea
ge
nt
s	
in
 t
he
 a
b
ov
e 
or
d
er
 in
 a
n 
R
N
as
e 
fr
ee
 c
en
tr
ifu
ge
 t
ub
e 
o
n 
ic
e.
		
D
iv
id
e	
th
e	
m
as
te
r	
m
ix
	in
to
	1
0	
po
rt
io
ns
	o
f	
40
	µ
l	e
ac
h	
in
to
	e
ith
er
	0
.2
	m
l	
op
tic
al
	(s
pe
ci
fic
al
ly
	f
or
	T
aq
M
an
	a
ss
ay
s;
	e
m
is
si
on
	fl
uo
re
sc
en
ce
	is
	r
ea
d	
th
ro
ug
h	
th
e	
ca
p)
	P
C
R
	t
ub
es
	o
r	
a	
96
	w
el
l	o
pt
ic
al
	P
C
R
	p
la
te
.		
Fi
na
lly
	a
dd
	1
0	
µl
	o
f	t
he
	in
di
vi
du
al
	R
N
A
	s
am
pl
e	
to
	e
ac
h	
tu
be
	o
r	
w
el
l.	
	A
ll	
sa
m
pl
es
	a
re
	te
st
ed
	in
	d
up
lic
at
e	
w
el
ls
.		
In
cl
ud
e 
se
ve
ra
l “
N
O
 
R
N
A
” 
ne
ga
tiv
e 
co
nt
ro
ls
 (N
TC
) b
y 
ad
d
in
g 
w
at
er
 in
st
ea
d
 o
f a
ny
 R
N
A
.  
In
cl
ud
e 
a 
p
os
iti
ve
 c
on
tr
ol
 o
r 
a 
d
ilu
tio
n 
se
rie
s 
of
 k
no
w
n 
q
ua
nt
iti
es
 
of
 p
os
iti
ve
 c
on
tr
ol
 R
N
A
 if
 s
et
tin
g 
up
 a
 q
ua
nt
ita
tiv
e 
as
sa
y.
C
yc
lin
g	
co
nd
iti
on
s	
(Q
IA
G
EN
	c
on
di
tio
ns
	fo
r	R
ea
l	T
im
e	
R
T-
P
C
R
):
1 
cy
cl
e:
 
45
 c
yc
le
s:
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°C
	fo
r	3
0	
m
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(R
T 
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tio
n)
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°C
	1
5	
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c
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°C
	fo
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m
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 (e
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e 
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tiv
at
io
n)
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°C
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tin
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d
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C
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In
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rp
re
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ti
o
n
Th
e 
fo
llo
w
in
g 
al
go
rit
hm
 is
 u
se
d
 b
y 
th
e 
A
rb
ov
ira
l D
ia
gn
os
tic
 L
ab
or
at
or
y 
at
 D
V
B
D
, C
D
C
 t
o 
ev
al
ua
te
 t
he
 T
aq
M
an
 r
es
ul
ts
.
P
os
iti
ve
:
•	
C
ut
of
f (
C
t) 
va
lu
e 
 3
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in
 d
up
lic
at
e 
w
el
ls
Eq
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vo
ca
l:
•	
C
t 
va
lu
e 
 3
8 
in
 o
ne
 o
f t
w
o 
w
el
ls
N
eg
at
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e:
•	
C
t 
va
lu
es
 >
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 in
 d
up
lic
at
e 
w
el
ls
A
ll	
po
si
tiv
e	
an
d	
eq
ui
vo
ca
l	s
am
pl
es
	a
re
	re
pe
at
ed
	w
ith
	a
	s
ec
on
d	
se
t	o
f	p
rim
er
/p
ro
be
s	
fo
r	c
on
fir
m
at
io
n.
		A
	p
os
iti
ve
	re
su
lt	
in
	a
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	o
f	t
he
	
ne
ga
tiv
e 
co
nt
ro
ls
 in
va
lid
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e 
en
tir
e 
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n.
  F
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 o
f t
he
 p
os
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ve
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ol
 to
 g
en
er
at
e 
a 
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si
tiv
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re
su
lt 
al
so
 in
va
lid
at
es
 th
e 
en
tir
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ru
n.
80 81
I. 
 R
N
A
 E
X
T
R
A
C
T
IO
N
A
vo
id
in
g
 C
o
nt
am
in
at
io
n 
an
d
 W
o
rk
in
g
 w
it
h 
R
N
A
•	
M
ai
nt
ai
n	
ph
ys
ic
al
ly
	s
ep
ar
at
ed
	w
or
k	
ar
ea
s;
	o
ne
	s
ho
ul
d	
be
	d
ed
ic
at
ed
	to
	p
re
-a
m
pl
ifi
ca
tio
n 
R
N
A
 w
or
k 
(R
N
A
 e
xt
ra
ct
io
n 
an
d
 
R
N
A
 a
d
d
iti
on
) a
nd
 t
he
 o
th
er
 t
o 
M
as
te
r 
m
ix
 p
ro
d
uc
tio
n.
•	
U
til
iz
e	
de
di
ca
te
d	
or
	s
ep
ar
at
e	
eq
ui
pm
en
t	w
ith
in
	p
re
-	
an
d	
po
st
-a
m
pl
ifi
ca
tio
n	
ar
ea
s,
	e
sp
ec
ia
lly
	p
ip
et
s	
an
d	
ce
nt
rif
ug
es
.
•	
A
lw
ay
s	
w
ea
r	g
lo
ve
s,
	e
ve
n	
w
he
n	
ha
nd
lin
g	
un
op
en
ed
	tu
be
s.
		
•	
Q
ui
ck
ly
	o
pe
n	
an
d	
cl
os
e	
tu
be
s	
an
d	
av
oi
d	
to
uc
hi
ng
	a
ny
	in
si
de
	p
or
tio
n.
•	
U
se
	R
N
as
e	
fre
e	
pl
as
tic
	d
is
po
sa
bl
e	
tu
be
s	
an
d	
pi
pe
t	t
ip
s.
•	
U
se
	a
er
os
ol
	b
lo
ck
	p
ip
et
	ti
ps
.
•	
U
se
	R
N
as
e	
fre
e	
w
at
er
.
•	
P
re
pa
re
	a
ll	
re
ag
en
ts
	o
n	
ic
e.
 1.
	
S
ol
id
	p
ha
se
	s
am
pl
es
	(m
os
qu
ito
es
	o
r	t
is
su
es
)	a
re
	fi
rs
t	h
om
og
en
iz
ed
	in
	a
n	
is
ot
on
ic
	b
uf
fe
r	t
o	
pr
od
uc
e	
a	
liq
ui
d	
ho
m
og
en
at
e.
		
R
N
A
	is
	e
xt
ra
ct
ed
	fr
om
	li
qu
id
	s
pe
ci
m
en
s	
(C
S
F	
or
	s
er
um
)	w
ith
ou
t	a
ny
	p
re
-t
re
at
m
en
t	a
s	
de
sc
rib
ed
	b
el
ow
.		
Ti
ss
ue
	s
pe
ci
m
en
s	
(~
10
m
m
3 )	
ar
e	
ho
m
og
en
iz
ed
	in
	1
	m
l	o
f	B
A
-1
	d
ilu
en
t	u
si
ng
	T
en
B
ro
ec
k	
tis
su
e	
gr
in
de
rs
.	M
os
qu
ito
	s
pe
ci
m
en
s	
ar
e	
ho
m
og
en
iz
ed
	
in
 T
en
B
ro
ec
k 
tis
su
e 
gr
in
d
er
s 
or
 b
y 
us
in
g 
th
e 
co
p
p
er
 c
la
d
 s
te
el
 b
ea
d
 (B
B
) g
rin
d
in
g 
te
ch
ni
q
ue
.  
W
ith
 b
ot
h 
te
ch
ni
q
ue
s 
th
e 
ho
m
og
en
at
es
	a
re
	c
la
rifi
ed
	b
y	
ce
nt
rif
ug
at
io
n	
in
	a
	m
ic
ro
ce
nt
rif
ug
e	
(e
.g
.,	
Ep
pe
nd
or
f)	
at
	m
ax
im
um
	s
pe
ed
	fo
r	5
	m
in
ut
es
	to
	p
el
le
t	a
ny
	
pa
rt
ic
ul
at
e 
m
at
er
ia
l. 
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tin
ue
d
)
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C
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io
n 
P
ro
to
co
l (
C
on
t.)
2.
	
Ex
tr
ac
t	R
N
A
	fr
om
	1
40
	µ
l	o
f	t
he
	li
qu
id
	s
pe
ci
m
en
	(C
S
F,
	s
er
um
,	o
r	c
la
rifi
ed
	h
om
og
en
at
e)
	u
si
ng
	th
e	
Q
iA
m
p	
vi
ra
l	R
N
A
	k
it	
(Q
IA
G
EN
	p
ar
t	#
	5
29
04
).	
	F
ol
lo
w
	th
e	
m
an
uf
ac
tu
re
r’s
	p
ro
to
co
l	e
xa
ct
ly
.		
N
O
T
E
: F
o
r 
m
o
sq
ui
to
 s
p
ec
im
en
s 
ad
d
 o
ne
 a
d
d
it
io
na
l 
w
as
h 
w
it
h 
A
W
1.
  E
xt
ra
ct
 a
t 
le
as
t 
tw
o 
ne
ga
tiv
e 
co
nt
ro
ls
 a
nd
 t
w
o 
p
os
iti
ve
 c
on
tr
ol
s 
al
on
g 
w
ith
 t
he
 t
es
t 
sp
ec
im
en
s.
  T
he
 
po
si
tiv
e	
co
nt
ro
ls
	s
ho
ul
d	
di
ffe
r	i
n	
th
e	
am
ou
nt
	o
f	t
ar
ge
t	R
N
A
	p
re
se
nt
	(i
.e
.,	
a	
pr
e-
de
te
rm
in
ed
	h
ig
h	
po
si
tiv
e	
an
d	
a	
lo
w
	p
os
iti
ve
).	
	
Th
e	
vo
lu
m
e	
of
	s
am
pl
e	
ex
tr
ac
te
d	
ca
n	
be
	g
re
at
er
	o
r	l
es
s	
th
an
	th
e	
st
an
da
rd
	v
ol
um
e	
st
at
ed
	in
	th
e	
Q
IA
G
EN
	p
ro
to
co
l	(
14
0	
µl
)	
w
ith
 t
he
 a
p
p
ro
p
ria
te
 a
d
ju
st
m
en
ts
 t
o 
al
l o
th
er
 v
ol
um
es
 in
 t
he
 p
ro
to
co
l.
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M
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N
T
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O
D
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 C
A
P
T
U
R
E
 E
N
Z
Y
M
E
-L
IN
K
E
D
 I
M
M
U
N
O
S
O
R
B
E
N
T
 A
S
S
A
Y
 P
R
O
T
O
C
O
L
In
tr
od
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tio
n
A
ss
ay
s	
th
at
	d
et
ec
t	v
ira
l	s
pe
ci
fic
	im
m
un
og
lo
bu
lin
	M
	(I
gM
)	a
re
	a
dv
an
ta
ge
ou
s	
be
ca
us
e	
th
ey
	d
et
ec
t	a
nt
ib
od
ie
s	
pr
od
uc
ed
	d
ur
in
g	
th
e	
fir
st
	fe
w
	d
ay
s	
af
te
r	o
ns
et
	o
f	c
lin
ic
al
	s
ym
pt
om
s	
in
	a
	p
rim
ar
y	
in
fe
ct
io
n.
	T
hi
s	
ob
vi
at
es
	th
e	
ne
ed
	fo
r	c
on
va
le
sc
en
t-
ph
as
e	
sp
ec
im
en
s	
in
	m
an
y	
ca
se
s.
	Ig
M
	c
ap
tu
re
	is
	th
e	
op
tim
al
	a
pp
ro
ac
h	
to
	Ig
M
	d
et
ec
tio
n:
	
it	
is
	s
im
pl
e,
	s
en
si
tiv
e,
	a
nd
	is
	a
pp
lic
ab
le
	to
	s
er
um
	a
nd
	c
er
eb
ro
sp
in
al
	fl
ui
d	
(C
S
F)
	s
am
pl
es
	fr
om
	a
	v
ar
ie
ty
	o
f	a
ni
m
al
	
sp
ec
ie
s	
(e
.g
.,	
hu
m
an
,	e
qu
in
e,
	a
vi
an
).	
	F
al
se
-p
os
iti
ve
	re
ac
tio
ns
	d
ue
	to
	rh
eu
m
at
oi
d	
fa
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 c
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ca
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 t
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m
al
	a
nt
ig
en
s	
ca
n	
be
	s
to
re
d	
at
	−
20
o C
	fo
r	a
n	
un
de
fin
ed
	p
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 c
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 d
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	re
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th
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ea
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 d
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at
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d	
0.
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m
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 d
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m
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iti
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b
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 m
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 c
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 b
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at
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f r
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ce
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at
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m
ay
	re
fle
ct
	te
st
in
g	
of
	a
n	
ac
ut
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ne
d	
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at
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M
,	a
nd
	re
m
ai
ns
	d
et
ec
ta
bl
e	
un
til
	lo
ng
	a
ft
er
	Ig
M
	c
ea
se
s	
to
	b
e	
pr
es
en
t.	
	U
si
ng
	th
e	
Ig
G
-E
LI
S
A
	in
	
pa
ra
lle
l	w
ith
	th
e	
Ig
M
	A
nt
ib
od
y	
C
ap
tu
re
	E
nz
ym
e-
lin
ke
d	
im
m
un
os
or
be
nt
	a
ss
ay
		(
M
A
C
-E
LI
S
A
),	
on
e	
ca
n	
ob
se
rv
e	
th
e 
re
la
tiv
e 
ris
es
 a
nd
 f
al
ls
 in
 a
nt
ib
o
d
y 
le
ve
ls
 in
 p
ai
re
d
 s
er
um
 s
am
p
le
s.
  T
he
 t
es
t 
is
 s
im
p
le
 a
nd
 s
en
si
tiv
e.
 It
 is
 
ap
pl
ic
ab
le
	to
	s
er
um
	s
pe
ci
m
en
s	
bu
t	n
ot
	g
en
er
al
ly
	to
	C
S
F	
sa
m
pl
es
.	F
al
se
-p
os
iti
ve
	re
ac
tio
ns
	d
ue
	to
	r
he
um
at
oi
d	
fa
ct
o
r 
ar
e 
m
in
im
iz
ed
.
P
rin
ci
p
le
Th
e	
Ig
G
-E
LI
S
A
	p
ro
vi
de
s	
a	
us
ef
ul
	a
lte
rn
at
iv
e	
to
	im
m
un
ofl
uo
re
sc
en
ce
	fo
r	i
de
nt
ifi
ca
tio
n	
of
	a
	v
ira
l	i
so
la
te
	o
r	
do
cu
m
en
ta
tio
n	
of
	a
	s
er
ol
og
ic
	re
sp
on
se
.		
Ig
G
-E
LI
S
A
	is
	le
ss
	s
ub
je
ct
iv
e	
th
an
	im
m
un
ofl
uo
re
sc
en
ce
	a
nd
	la
rg
e	
nu
m
be
rs
	o
f	s
am
pl
es
	c
an
	b
e	
pr
oc
es
se
d.
	V
ira
l	g
ro
up
-r
ea
ct
iv
e	
m
on
oc
lo
na
l	a
nt
ib
od
y	
is
	c
oa
te
d	
on
	a
	9
6-
w
el
l	
pl
at
e,
	fo
llo
w
ed
	s
eq
ue
nt
ia
lly
	b
y	
kn
ow
n	
vi
ra
l	a
nt
ig
en
,	p
at
ie
nt
	s
er
um
,	e
nz
ym
e-
co
nj
ug
at
ed
	h
um
an
	Ig
G
,	a
nd
	la
st
ly
	
su
bs
tr
at
e	
fo
r	t
he
	c
on
ju
ga
te
		u
se
d.
	T
hi
s	
co
ns
tit
ut
es
	th
e	
Ig
G
-E
LI
S
A
	u
se
d	
at
	th
e	
A
rb
ov
ira
l	D
ia
gn
os
tic
	L
ab
or
at
or
y,
	
D
V
B
D
, C
D
C
.
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S
af
et
y 
Th
e 
p
ro
ce
d
ur
e 
sh
ou
ld
 b
e 
p
er
fo
rm
ed
 u
nd
er
 la
b
or
at
or
y 
sa
fe
ty
 c
on
d
iti
on
s 
th
at
 t
ak
e 
in
to
 c
on
si
d
er
at
io
n 
th
e 
p
ot
en
tia
l 
in
fe
ct
io
us
	n
at
ur
e	
of
	th
e	
se
ru
m
	s
pe
ci
m
en
s	
in
vo
lv
ed
.	L
ab
	c
oa
t,	
gl
ov
es
,	a
nd
	a
	la
m
in
ar
	fl
ow
	h
oo
d	
is
	re
co
m
m
en
de
d.
M
at
er
ia
ls
 a
nd
R
ea
ge
nt
s
C
o
at
in
g
 b
uf
fe
r:
	C
ar
bo
na
te
/b
ic
ar
bo
na
te
	b
uf
fe
r	p
H
	9
.6
,	1
.5
9g
	N
a2
C
O
3	
+	
2.
93
g	
N
aH
C
O
3	
di
lu
te
d	
in
	1
L	
w
at
er
.
W
as
h 
b
uf
fe
r:
 P
ho
sp
ha
te
	b
uf
fe
re
d	
sa
lin
e	
(P
B
S
),	
0.
05
%
	T
w
ee
n	
20
,	p
H
	7
.2
.	P
B
S
	is
	a
va
ila
bl
e	
in
	p
ow
de
re
d	
fo
rm
	
fr
om
 m
ul
tip
le
 c
om
m
er
ci
al
 s
ou
rc
es
.
B
lo
ck
in
g
 b
uf
fe
r:
 3
%
	g
oa
t	s
er
um
,	1
%
	T
w
ee
n-
20
,	i
n	
P
B
S
.
C
o
at
in
g
 a
nt
ib
o
d
y:
 G
ro
up
-s
pe
ci
fic
	m
on
oc
lo
na
l	a
nt
ib
od
y,
	p
re
vi
ou
sl
y	
tit
ra
te
d.
V
ir
al
 a
nt
ig
en
: S
uc
ro
se
-a
ce
to
ne
	e
xt
ra
ct
ed
	s
uc
kl
in
g	
m
ou
se
	b
ra
in
	v
ira
l	a
nt
ig
en
s,
	n
on
-in
fe
ct
io
us
,	p
re
vi
ou
sl
y	
tit
ra
te
d.
N
o
rm
al
 a
nt
ig
en
:	S
uc
ro
se
-a
ce
to
ne
	e
xt
ra
ct
ed
	s
uc
kl
in
g	
m
ou
se
	b
ra
in
	a
nt
ig
en
	fr
om
	m
oc
k-
in
fe
ct
ed
	a
ni
m
al
s.
D
et
ec
ti
ng
 a
nt
ib
o
d
y 
co
nj
ug
at
e:
 A
lk
al
in
e	
ph
os
ph
at
as
e-
co
nj
ug
at
ed
	g
oa
t	a
nt
i-h
um
an
	Ig
G
	F
cγ
 p
or
tio
n,
 p
re
vi
ou
sl
y.
 
tit
ra
te
d	
(J
ac
ks
on
	Im
m
un
or
es
ea
rc
h	
ca
t#
	1
09
-0
55
-0
98
)
S
ub
st
ra
te
:	3
	m
g/
m
l	p
-n
itr
op
he
ny
l	p
ho
sp
ha
te
,	d
is
od
iu
m
	(S
ig
m
a	
10
4,
	S
ig
m
a	
di
ag
no
st
ic
s	
ca
t#
	1
04
-1
05
)	i
n	
1M
	T
ris
	
(b
as
e)
	p
H
	8
.0
	(n
ot
e:
	th
e	
Tr
is
	re
qu
ire
s	
co
ns
id
er
ab
le
	c
on
c.
	H
C
l	f
or
	th
e	
pH
	a
dj
us
tm
en
t).
S
to
p
 s
o
lu
ti
o
n:
 3
M
 N
aO
H
.
(C
on
tin
ue
d
)
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A
pp
en
di
x 
C
. I
gM
 a
nd
 I
gG
 S
er
ol
og
ic
 A
ss
ay
 P
ro
to
co
ls
 (
C
on
t.)
Ig
G
 E
N
Z
Y
M
E
-L
IN
K
E
D
 I
M
M
U
N
O
S
O
R
B
E
N
T
 A
S
S
A
Y
 P
R
O
T
O
C
O
L
M
at
er
ia
ls
 a
nd
R
ea
ge
nt
s
P
la
te
s:
	Im
m
ul
on
	II
	H
B
	fl
at
-b
ot
to
m
ed
	9
6	
w
el
l	p
la
te
s.
	D
yn
at
ec
h	
Te
ch
no
lo
gi
es
	c
at
#	
34
55
.
M
ic
ro
p
la
te
 w
as
he
r
M
ic
ro
p
la
te
 r
ea
d
er
In
cu
b
at
or
S
in
gl
e	
an
d	
m
ul
ti-
ch
an
ne
l	p
ip
et
to
rs
R
ea
ge
nt
 r
es
er
vo
irs
Z
ip
lo
c 
b
ag
s,
 p
ap
er
 t
ow
el
s
C
lin
ic
al
 
sp
ec
im
en
s 
A
cu
te
 a
nd
 c
on
va
le
sc
en
t 
hu
m
an
 s
er
um
N
ot
e:
	S
to
re
	a
ll	
di
ag
no
st
ic
	s
pe
ci
m
en
s	
at
	4
°C
	p
rio
r	t
o	
te
st
in
g,
	a
nd
	a
t	-
20
°C
	a
fte
r	a
ll	
an
tic
ip
at
ed
	te
st
in
g	
ha
s	
be
en
	
co
m
pl
et
ed
.	A
vo
id
	re
pe
at
ed
	fr
ee
ze
-t
ha
w
	c
yc
le
s.
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P
ro
ce
d
ur
e
N
ot
e:
	T
he
	fo
llo
w
in
g	
pr
oc
ed
ur
e	
in
cl
ud
es
	in
fo
rm
at
io
n	
on
	q
ua
lit
y	
co
nt
ro
l	a
nd
	in
te
rp
re
ta
tio
n.
	E
ac
h	
se
ru
m
	s
pe
ci
m
en
	
is
 t
es
te
d
 in
 t
rip
lic
at
e 
on
 b
ot
h 
vi
ra
l a
nd
 n
or
m
al
 a
nt
ig
en
s.
 E
ig
ht
 t
es
t 
sp
ec
im
en
s 
ca
n 
b
e 
an
al
yz
ed
 p
er
 p
la
te
. 
1.
	U
si
ng
	a
	fi
ne
-t
ip
pe
d	
pe
rm
an
en
t	m
ar
ke
r,	
nu
m
be
r	a
nd
	la
be
l	t
he
	p
la
te
s.
	Id
en
tif
y	
th
e	
lo
ca
tio
n	
of
	e
ac
h	
cl
in
ic
al
	
sp
ec
im
en
	(S
1−
S
8)
	b
y	
us
in
g	
th
e	
ap
pr
op
ria
te
	la
bo
ra
to
ry
	c
od
e	
nu
m
be
r.	
To
 k
ee
p
 t
im
in
g 
of
 r
ea
ge
nt
 a
d
d
iti
on
 
co
ns
is
te
nt
, p
ro
ce
ss
 p
la
te
s 
in
 t
he
 o
rd
er
 t
ha
t 
th
ey
 a
re
 n
um
b
er
ed
 d
ur
in
g 
al
l s
te
p
s 
of
 t
he
 p
ro
ce
d
ur
e.
 P
la
te
s 
sh
ou
ld
	b
e	
ke
pt
	in
	a
n	
en
cl
os
ed
,	h
um
id
ifi
ed
	e
nv
iro
nm
en
t	d
ur
in
g	
al
l	i
nc
ub
at
io
n	
tim
es
	w
ith
	th
e	
ex
ce
pt
io
n	
of
	th
e	
co
at
in
g 
st
ep
. A
 la
rg
e 
zi
p
lo
c 
b
ag
 c
on
ta
in
in
g 
a 
m
oi
st
 p
ap
er
 t
ow
el
 w
or
ks
 w
el
l f
or
 t
hi
s 
p
ur
p
os
e.
2.
	C
oa
t	t
he
	in
ne
r	6
0	
w
el
ls
	o
f	9
6	
w
el
l	p
la
te
s	
w
ith
	7
5µ
l/w
el
l	o
f	t
he
	a
pp
ro
pr
ia
te
	g
ro
up
-r
ea
ct
iv
e	
m
on
oc
lo
na
l	
an
tib
od
y 
d
ilu
te
d
 in
 c
oa
tin
g 
b
uf
fe
r 
ac
co
rd
in
g 
to
 p
rio
r 
tit
ra
tio
n.
  I
nc
ub
at
e 
at
 4
°C
 o
ve
rn
ig
ht
.
3.
	D
um
p	
ou
t	t
he
	c
oa
tin
g	
an
tib
od
y	
an
d	
bl
ot
	p
la
te
s	
on
	p
ap
er
	to
w
el
s.
	B
lo
ck
	p
la
te
s	
w
ith
	2
00
µl
	b
lo
ck
in
g	
bu
ffe
r	p
er
	
w
el
l. 
In
cu
b
at
e 
at
 r
o
o
m
 t
em
p
er
at
ur
e 
fo
r 
30
 m
in
ut
es
.
4.
	W
as
h	
w
el
ls
	5
X	
w
ith
	w
as
h	
bu
ffe
r	b
y	
us
in
g	
an
	a
ut
om
at
ic
	p
la
te
	w
as
he
r.	
W
el
ls
	s
ho
ul
d	
be
	fi
lle
d	
to
	th
e	
to
p	
ea
ch
	c
yc
le
.
5.
	D
ilu
te
	v
ira
l	a
nt
ig
en
	in
	w
as
h	
bu
ffe
r	a
cc
or
di
ng
	to
	a
	p
re
vi
ou
s	
tit
ra
tio
n.
		A
dd
	5
0µ
l	p
er
	w
el
l	t
o	
th
e	
le
ft	
th
re
e	
w
el
ls
	o
f	e
ac
h	
se
ru
m
	b
lo
ck
.	T
o	
th
e	
rig
ht
	th
re
e	
w
el
ls
	o
f	e
ac
h	
bl
oc
k,
	a
dd
	5
0µ
l	p
er
	w
el
l	o
f	n
or
m
al
	a
nt
ig
en
	d
ilu
te
d	
in
	w
as
h	
bu
ffe
r	t
o	
th
e 
sa
m
e 
co
nc
en
tr
at
io
n 
as
 th
e 
vi
ra
l a
nt
ig
en
.  
In
cu
ba
te
 o
ve
rn
ig
ht
 a
t 4
°C
	in
	a
	h
um
id
ifi
ed
	c
ha
m
be
r.
6.
	W
as
h	
5X
.
7.
	A
dd
	5
0µ
l	p
er
	w
el
l	o
f	t
he
	p
at
ie
nt
’s
	s
er
um
	(S
)	d
ilu
te
d	
1:
40
0	
in
	w
as
h	
bu
ffe
r	t
o	
a	
bl
oc
k	
of
	s
ix
	w
el
ls
.	A
dd
	p
os
iti
ve
	
co
nt
ro
l h
um
an
 s
er
um
 (R
ef
) d
ilu
te
d
 in
 w
as
h 
b
uf
fe
r 
ac
co
rd
in
g 
to
 a
 p
re
vi
ou
s 
tit
ra
tio
n,
 a
nd
 a
 n
eg
at
iv
e 
hu
m
an
 
se
ru
m
	c
on
tr
ol
	(N
)	d
ilu
te
d	
1:
40
0	
in
	w
as
h	
bu
ffe
r	t
o	
a	
bl
oc
k	
of
	6
	w
el
ls
	e
ac
h.
	In
cu
b
at
e 
p
la
te
s 
fo
r 
o
ne
 h
o
ur
 a
t 
37
°C
	in
	a
	h
um
id
ifi
ed
	c
ha
m
be
r.
(C
on
tin
ue
d
)
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A
pp
en
di
x 
C
. I
gM
 a
nd
 I
gG
 S
er
ol
og
ic
 A
ss
ay
 P
ro
to
co
ls
 (
C
on
t.)
Ig
G
 E
N
Z
Y
M
E
-L
IN
K
E
D
 I
M
M
U
N
O
S
O
R
B
E
N
T
 A
S
S
A
Y
 P
R
O
T
O
C
O
L
P
ro
ce
d
ur
e
8.
	W
as
h	
5X
.
9.
	A
dd
	5
0µ
l	p
er
	w
el
l	o
f	a
lk
al
in
e	
ph
os
ph
at
as
e-
co
nj
ug
at
ed
	g
oa
t	a
nt
i-h
um
an
	Ig
G
	d
ilu
te
d	
in
	b
lo
ck
in
g	
bu
ffe
r,	
ac
co
rd
in
g 
to
 p
rio
r 
tit
ra
tio
n.
  I
nc
ub
at
e 
fo
r 
o
ne
 h
o
ur
 a
t 
37
°C
 in
 a
 h
um
id
 c
ha
m
b
er
.
10
.	T
ur
n	
on
	p
la
te
	re
ad
er
	to
	w
ar
m
	u
p	
an
d	
di
ss
ol
ve
	s
ub
st
ra
te
	ta
bl
et
s	
in
	tr
is
	b
uf
fe
r	a
bo
ut
	1
5	
m
in
ut
es
	p
rio
r	t
o	
ad
d
in
g 
it 
to
 t
he
 p
la
te
s.
11
.	W
as
h	
pl
at
es
	5
X	
tw
ic
e.
	T
ur
n	
th
e	
pl
at
es
	1
80
o 	i
n	
th
e	
w
as
he
r	a
fte
r	t
he
	fi
rs
t	s
er
ie
s	
of
	fi
ve
	c
yc
le
s.
	T
hi
s	
pr
om
ot
es
	
co
ns
is
te
nt
 r
es
ul
ts
.
12
.	W
hi
le
	th
e	
pl
at
e	
is
	a
t	r
oo
m
	te
m
pe
ra
tu
re
,	a
dd
	7
5µ
l	p
er
	w
el
l	o
f	S
ig
m
a	
10
4	
su
bs
tr
at
e	
to
	a
ll	
w
el
ls
.	I
m
m
ed
ia
te
ly
	
co
ve
r 
p
la
te
s 
to
 b
lo
ck
 o
ut
 li
gh
t.
  I
nc
ub
at
e 
at
 r
oo
m
 t
em
p
er
at
ur
e 
fo
r 
30
 m
in
ut
es
. A
 y
el
lo
w
 c
ol
or
 w
ill
 d
ev
el
op
 in
 
an
tib
od
y-
po
si
tiv
e	
w
el
ls
.
13
.	A
dd
	3
5µ
l	p
er
	w
el
l	o
f	s
to
p	
so
lu
tio
n	
to
	a
ll	
w
el
ls
,	i
nc
lu
di
ng
	th
e	
ou
te
r	r
ow
s	
of
	w
el
ls
	o
n	
th
e	
pl
at
e	
(th
e	
pl
at
e	
re
ad
er
	
its
el
f s
ho
ul
d
 b
e 
se
t 
to
 z
er
o 
on
 s
om
e 
of
 t
he
se
 w
el
ls
). 
 R
ea
ct
iv
e 
w
el
ls
 w
ill
 r
em
ai
n 
a 
ye
llo
w
 c
ol
or
.  
A
llo
w
 p
la
te
s 
to
	s
it	
at
	ro
om
	te
m
pe
ra
tu
re
	fo
r	o
ne
	m
in
ut
e.
		R
ea
d	
pl
at
es
	in
	m
ic
ro
tit
er
	p
la
te
	re
ad
er
	b
y	
us
in
g	
a	
40
5	
nm
	fi
lte
r.
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P
ra
ct
ic
al
co
ns
id
er
at
io
ns
1.
	P
la
te
s	
ca
n	
be
	c
oa
te
d	
an
d	
ke
pt
	a
t	4
o C
 fo
r 
up
 t
o 
a 
w
ee
k.
2.
	U
nd
ilu
te
d	
co
nt
ro
l	s
er
a	
ca
n	
be
	s
to
re
d	
at
	4
o C
 fo
r 
up
 t
o 
tw
o 
w
ee
ks
.
3.
	R
ec
on
st
itu
te
d,
	u
nd
ilu
te
d	
vi
ra
l	a
nd
	n
or
m
al
	a
nt
ig
en
s	
ca
n	
be
	s
to
re
d	
at
	−
20
o C
	fo
r	a
n	
un
de
fin
ed
	p
er
io
d	
of
	ti
m
e.
4.
	T
es
t	a
nd
	c
on
tr
ol
	s
er
a	
ca
n	
be
	d
ilu
te
d	
to
	th
e	
w
or
ki
ng
	d
ilu
tio
ns
	a
nd
	re
fr
ig
er
at
ed
	o
ne
	d
ay
	p
rio
r	t
o	
us
e.
	A
nt
ig
en
s	
an
d
 c
on
ju
ga
te
 m
us
t 
b
e 
d
ilu
te
d
 t
o
 t
he
 w
o
rk
in
g
 d
ilu
ti
o
ns
 im
m
ed
ia
te
ly
 p
ri
o
r 
to
 u
se
.
Th
e	
Ig
G
-E
LI
S
A
	s
ho
ul
d	
be
	re
st
an
da
rd
iz
ed
	p
er
io
di
ca
lly
.	T
hi
s	
sh
ou
ld
	o
cc
ur
	w
he
n	
ne
w
	lo
t	n
um
be
rs
	o
f	r
ea
ge
nt
s	
ar
e	
in
tr
od
uc
ed
, a
nd
 a
t 
th
e 
ve
ry
 le
as
t,
 o
nc
e 
a 
ye
ar
. I
t 
is
 r
ec
om
m
en
d
ed
 t
ha
t 
th
e 
m
ea
n 
op
tic
al
 d
en
si
ty
 o
f t
he
 p
os
iti
ve
 
co
nt
ro
l	s
er
um
	re
ac
te
d	
on
	th
e	
vi
ra
l	a
nt
ig
en
	b
e	
se
t	t
o	
ap
pr
ox
im
at
el
y.
	1
.0
.	T
he
	n
or
m
al
	c
on
tr
ol
	s
er
um
	re
ac
te
d	
on
	th
e	
vi
ra
l	a
nt
ig
en
	s
ho
ul
d	
be
	a
ro
un
d	
0.
2	
(th
is
	v
ar
ie
s)
.	T
he
	s
ta
nd
ar
di
za
tio
n	
of
	re
ag
en
ts
	is
	n
or
m
al
ly
	a
ch
ie
ve
d	
vi
a	
tit
ra
tio
n,
	
al
w
ay
s 
co
m
p
ar
in
g 
th
e 
op
tic
al
 d
en
si
tie
s 
of
 t
he
 r
ea
ge
nt
s 
w
he
n 
re
ac
te
d
 o
n 
vi
ra
l a
nd
 n
or
m
al
 a
nt
ig
en
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Appendix D. Example of a Case Report Form
(Continued)
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Appendix D. Example of a Case Report Form (Cont.)
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NOTIFICATION_____________Region______________	
A case or outbreak of [EVENT OF HEALTH] has occurred in the town 
[LOCATION], commune, region [NAME Municipalities and Regions] on 
[MONTH and YEAR or time period]. 
As of [Report Date], [CASE NUMBER] of [EVENT OF HEALTH] presenting with 
[MAIN SIGNS AND SYMPTOMS] were seen at [INSTITUTION OR SECTOR 
OR OTHER COMMUNITY].  These cases are occurring in an areas with an 
approximate population of [ N ° OF INHABITANTS or exposed population]. 
The cases have occurred between the [START DATE, WEEK EPIDEMIOLOGICAL] 
and [DATE TO END or TODAY]. The affected area is mainly [urban or rural] and 
has previously presented occasional outbreaks of [PREVIOUS OUTBREAKS]. 
The most striking feature of the cases is [FEATURE PERSON: SEX, AGE, OR 
OTHER TO DEFINE CHARACTERISTICS of people affected]. 
Of all the cases, [# DECEASED] died and [# HOSPITALIZED] requiring 
hospitalization.  Cases either dying or requiring hospitalization have [COURSE 
TYPE: DEATH, HIGH WITHOUT COMPLICATIONS, AFTERMATH, ETC]. 
[# samples] sample(s) of [SPECIMEN TYPE] have been taken and sent to [LAB] 
for	processing	where	testing	is	ongoing	or	has	confirmed	[Etiologic	agent].	
Epidemiological research indicates that the outbreak was produced by 
[POSSIBLE MECHANISM, SOURCE, exposure factor]. 
The	control	actions	have	been	taken	are	as	follows: [ACTION] 
Note:	 The	 immediate	 notification	 must	 include	 whatever	 is	 possible	 to	
complete the learning of the outbreak. Once investigated, it is sent back the 
full	format	to	regional	World	Health	Organization	office.	
Appendix E. Report for an Event or Outbreak 
 of Public Health Importance
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There are a number of vector control procedures that should be considered 
to mitigate the risk of CHIKV expansion in an area (Table F1). 
Appendix F. Vector Control Procedures
Table F1. vector control procedures
Environmental management
•	 Reduce	larval	habitats
•	 Manage	(wash/cover)	containers
•	 Discard/recycle	containers
•	 Reduce	human-vector	contact
•	 Install	window	screens	
Larval control
•	 Source	reduction
•	 Chemical	control
•	 Biological	control
Adult mosquito control
•	 Use	of	IT	bednets
•	 Use	of	IT	curtains
•	 Lethal	ovitraps
•	 Space	sprays
•	 Indoor	residual	treatments
Resistance testing
Operational research and  
efficacy evaluation
Chemica l  Cont ro l  o f  Larva l  Hab i ta t s
If potable water vessels cannot be screened or covered, they should be 
cleaned regularly or treated to stop larval production according to WHO 
Pesticide Evaluation Scheme (WHOPES) recommended practices for potable 
water.66	 Potential larval habitats that do not contain water intended for human 
consumption may be treated with larvicides listed in Table F2.  
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Table F2.  wHO-recommended compounds and formulations for 
control of mosquito larvae in container habitats.a 
Insecticide Formulationb Dosagec
WHO hazard 
classification
of active 
ingredientd
Organophosphates
Pirimiphos-methyl EC 1 III
Temephos EC,GR 1 U
Insect growth regulators
Diflubenzuron DT,GR, WP 0.02-0.25 U
rs-methoprenee EC 1 U
Novaluron EC 0.01-0.05 NA
Pyriproxyfene GR 0.01 U
Biopesticides
Bacillus thuringiensise 
israelenses
WG 1-5	mg/L U
Spinosad DT,GR,SC 0.1-0.5 U
a WHO recommendations on the use of pesticides in public health are valid only 
if	linked	to	WHO	specifications	for	their	quality	control.	WHO	specifications	for	
public	health	pesticides	are	available	at	http://www.who.int/whopes/quality/en/.	
Instructions must always be followed when using insecticides.
b DT=tablet	for	direct	application;	GR=granule;	EC=emulsifiable	concentrate;	
WG=water-dispersible	granule;	WP=wettable	power;	SC=suspension	
concentrate.
c  mg/L	of	active	ingredient	for	control	of	container-breeding	mosquitoes.
d Class	II=moderately	hazardous;	Class	III=slightly	hazardous;	Class	U=Unlikely	to	
pose an acute hazard in normal use; NA=not available.
e Can be used at recommended dosages in potable water.
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Space  Sprays  fo r  Adu l t  Mosqu i to  Cont ro l
Space sprays for Ae. aegypti and Ae. albopictus control are most effective 
when the inside of houses and associated yards are individually treated with 
handheld sprayers. Repeated applications are required to kill newly emerging 
adults. In an epidemic response, space sprays should be carried out with 
handheld	 sprayers	 whenever	 possible,	 or	 with	 truck-mounted	 sprayers	 to	
increase speed of coverage, every two to three days.66	 Attention to resistance 
testing, calibration of equipment, droplet size, and timing of application are 
all critical to effective use of these tools.66	 Large-scale	 truck	 and	 airplane	
based application of pesticides is generally not effective in controlling Ae. 
aegypti when used alone.76	Large-scale	space	spraying	must	be	used	as	a	
component of an IVM program to be effective. Table F3 provides information 
on insecticides suitable to Ae. aegypti and Ae. albopictus control. 
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Table F3.  Examples of insecticides for cold aerosol or thermal 
fog application against mosquitoes.a
Insecticide Chemical
Dosage of active 
ingredient  
(g/ha)
WHO hazard 
classification
of active 
ingredientcCold 
aerosols 
Thermal 
fogsb
Fenitrothion Organophosphate 	250−300 250−300 II
Malathion Organophosphate 112−600 500−600 III
Pirimiphos 
-methyl
Organophosphate 230−330 180−200 III
Bioresmethrin Pyrethroid 5 10 U
Cyfluthrin Pyrethroid 1−2 1−2 II
Cypermethrin Pyrethroid 1−3 − II
Cyphenothrin Pyrethroid 2−5 5−10 II
d,d-trans-
Cyphenothrin
Pyrethroid 1−2 2.5−5 NA
Deltamethrin Pyrethroid 0.5−1.0 0.5−1.0 II
D-Phenothrin Pyrethroid 5−20 - U
Etofenprox Pyrethroid 10−20 10−20 U
λ Cyhalothrin Pyrethroid 1.0 1 II
Permethrin Pyrethroid 5 10 II
Resmethrin Pyrethroid 2−4 4 III
a	 Adapted	 from:	Pesticides	and	 their	application	 for	 the	control	of	vectors	and	
pests of public health importance.77 Label instructions must always be followed 
when using insecticides.
b	 The	 strength	 of	 the	 finished	 formulation	 when	 applied	 depends	 on	 the	
performance of the spraying equipment used.
c	 Class	II=moderately	hazardous;	class	III=slightly	hazardous;	class	U=unlikely	to	
pose an acute hazard in normal use; NA=not available.
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Indoor  Res idua l  Sprays  fo r  Adu l t  Mosqu i to  Cont ro l
Traditionally, Indoor Residual Sprays (IRS) have been used most successfully 
against	malaria	vectors	(Table	F4).	IRS	treatment	should	be	effective	against	Ae. 
aegypti,	which	rests	indoors,	though	it	may	be	difficult	to	apply	operationally.	
Generally, all interior walls and ceilings of a house are treated. For control 
of Ae. aegypti, it is important to treat bedrooms, closets, the undersides of 
beds, and other dark areas where Ae. aegypti adults rest before and after 
taking a bloodmeal. Residents should be informed that IRS are safe when 
applied according to the label, but that individuals with health concerns, such 
as those with asthma or allergies, should take measures to reduce or eliminate 
exposure during the application process.
Res i s tance  Tes t ing
Frequent application of the same insecticide or class of insecticide may select 
for individual mosquitoes that are able to survive pesticide applications.78 
Resistance is a heritable change in the sensitivity of a mosquito population to 
an insecticide that may lead to failure of the pesticide to yield the expected 
degree of control.   
The insecticides available for use as adulticides are limited, and fall into three 
chemical	 classes:	 organophosphates,	 carbamates,	 and	 pyrethroids.	 Some	
products for larviciding have different modes of actions, such as insect growth 
regulators and microbials tools.78 However, the most commonly used product 
for controlling larvae of Ae. aegypti in containers is the organophosphate 
temephos.  Resistance to temephos has been detected in multiple Ae. aegypti 
populations in the Americas79,	 80 and poses a serious threat to Ae. aegypti 
control. Little information is available about resistance in Ae. albopictus 
populations in the Region.
Control programs must include a resistance monitoring program81−83	
(additional	references	are	available	at	http://www.who.int/whopes/resistance/
en/)	to	assess	efficacy	and	to	establish	a	pesticide	rotation	plan	to	mitigate	the	
development of resistance.
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Table F4. wHO recommended insecticides for use as 
indoor residual sprays.a
Insecticide 
compounds and 
formulationsb
Class 
groupc
Dosage g 
a.i./m2
Mode of 
action
Duration 
of effective 
action 
(months)
DDT WP OC 1−2 contact >6
Malathion WP OP 2 contact 2-3
Fenitrothion WP OP 2
contact & 
airborne
3-6
Pirimiphos-methyl	WP	
& EC
OP 1−2
contact & 
airborne
2-3
Bendiocarb WP C 0.1−0.4
contact & 
airborne
2-6
Propoxur WP C 1−2
contact & 
airborne
3-6
Alpha-cupermethrin	
WP & SC
PY 0.02−0.03 contact 4-6
Bifenthrin WP PY 0.025−0.05 contact 3-6
Cyfluthrin	WP PY 0.02−0.05 contact 3-6
Deltamethrin WP, WG PY 0.02−0.025 contact 3-6
Etofenprox WP PY 0.1−0.3 contact 3-6
Lambda-cyhalothrin	
WP, CS
PY 0.02−0.03 contact 3-6
a	 Available	at	(http://www.who.int/whopes/Insecticides_IRS_Malaria_09.pdf).
b	 CS	 =	 capsule	 suspension;	 EC	 =	 emulsifiable	 concentrate;	 SC	 =	 suspension	
concentrate; WG = water dispersible granule; WP = wettable
c OC = Organochlorines; OP = Organophosphates; C = Carbamates; PY = 
Pyrethroids
Note: WHO recommendations on the use of pesticides in public health are valid 
only	if	linked	to	WHO	specifications	for	their	quality	control.		WHO	specifications	
for	public	health	pesticides	are	available	on	WHO’s	homepage	at	http://www.who.
int/whopes/quality/en/.
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Superv i s ion , Safe ty, and  Qua l i t y  Assurance
Continuous monitoring and supervision are required to ensure that staff 
are adequately trained and are following appropriately technical guidelines 
for pesticide application and personal safety.77 IVM programs must include 
a quality assurance program designed to monitor the effectiveness of the 
control activities. A quality assurance program should monitor applicator 
performance and control outcomes. Control failures may be due to 
misapplication, incomplete coverage, or insecticide resistance, and must 
be	 corrected	 immediately.	Quality	 assurance	 efforts	 should	 be	 continuous,	
systematic, and independent. 
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Virus containment efforts should be initiated upon discovery of a CHIKV case 
or cluster (introduced or autochthonous transmission), simultaneous with 
activating the local emergency response capacity. The purpose of containment 
is to eliminate the newly introduced CHIKV and to prevent its spread by 
implementation of intensive vector control measures. This concept has been 
applied	to	contain	the	invasion	and	spread	of	dengue	viruses	in	non-endemic	
areas.84  Even if CHIKV spreads into a country’s urban area, containment 
should be considered a primary strategy to avoid its spread elsewhere in 
that country and into neighboring countries. Application of vector control 
measures should start at homes of detected CHIKV cases (or at a suspected 
site of infection) and should be applied to the entire neighborhood.  Because 
of	delays	in	case	detection	and	notification,	it	is	likely	that	CHIKV	may	have	
already spread to other parts of the neighborhood.85 Request the involvement 
of local authorities to gain access to closed or abandoned properties. The 
entire emergency containment operation needs to be conducted rapidly, 
so human and other resources devoted to this effort should be matched to 
the size of the containment area.  Malaria control personnel and others with 
suitable training may be utilized to accomplish goals of the containment effort.
The	following	actions	are	recommended	to	contain	an	introduction	of	CHIKV:
1. In addition to participating in a national communication effort, immediately 
inform the community (residents, schools, churches, businesses, etc.) of 
the CHIKV introduction.  Topics should include mode of spread, symptoms, 
advice to consult a physician if symptoms appear, and community 
involvement to eliminate standing water from containers and to allow health 
inspectors	into	homes	for	application	of	anti-mosquito	measures.		Prepare	
the community so that CHIKV containment operations can be conducted 
more	 efficiently	 and	 rapidly	 in	 residential	 and	 commercial	 properties,	 as	
well as in public spaces and parks.
Appendix G. Vector Control for CHIKV Containment
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2. Conduct indoor and outdoor insecticide applications to eliminate adult 
mosquitoes.  Details on insecticides, dosages, and precautions can be 
found in Table F3 and in WHO publications.66,	77,	86	
3. Simultaneously conduct container elimination/protection and larviciding to 
eliminate the production of new mosquitoes. Special attention should be 
given to cryptic or subterranean bodies of water that can produce Aedes 
mosquitoes, such as roof gutters, drains, wells, elevated water tanks, 
water meters, and even septic tanks.87 Water storage containers and 
animal drinking pans should be cleaned (by scrubbing and rinsing) and 
protected with tight covers.  Some containers, such as useful implements 
(paint trays, buckets) and bottles should be stored in a way to prevent 
them	from	collecting	water	(e.g.,	upside-down,	under	a	roof).	Large	objects	
that accumulate rain water (boats, cars) should be properly covered. 
Containers that cannot be prevented from holding water for any reason 
should be treated with a larvicide.  For example, containers holding water 
for animal or human consumption require the application of larvicides that 
have been licensed in the country for that particular purpose.  WHO’s 
approved	 larvicides	 used	 to	 treat	 potable	 water-storage	 containers	 are	
provided in Appendix F, in the section “Chemical control of larval habitats”. 
Pesticides	should	always	be	used	following	their	label	specifications.	For	
other	 larvicides	 that	 can	 be	 applied	 to	 containers	 holding	 non-potable	
water, see Table F2. 66,	77,	86,	88
4.	 Alternatively,	 or	 concurrently	with	 source	 reduction,	 residual	 insecticides	
can	 be	 applied	 to	 containers	 holding	 non-potable	 water	 (to	 inner/outer	
walls) to kill the larvae and pupae and to nearby outdoor surfaces to kill 
landing or resting adult mosquitoes. This type of insecticide application is 
done	with	hand-held	compression	sprayers	and	much	care	has	to	be	taken	
to	avoid	spraying	near	unprotected	water-storage	containers	or	pets.66,	77
5.	 Monitor	houses	and	buildings	in	the	neighborhoods	that	are	being	treated	
and implement special control rounds after working hours, weekends, and 
holidays	to	assure	that	nearly	100%	of	homes	and	businesses	are	treated.	
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Outbreak  In te rvent ion
Controlling an epidemic of CHIKV or a series of outbreaks over a larger 
geographic	scale	requires	the	following:
1. Activating a command center (Emergency Operations Center), either 
physical or virtual, where epidemiologists, entomologists and vector control 
specialists, educators, media communicators, etc., can jointly plan, work, 
and evaluate progress throughout the epidemic. Epidemiological services 
need to be organized so that daily, detailed reports are sent to all authorized 
personnel in the affected areas (states, municipalities). To be successful, 
it	will	 be	 necessary	 to	 establish	 an	 efficient	 system	of	 communications,	
allowing	 for	 feed-back	reports	and	the	receipt	of	acknowledgements	 (by	
e-mail,	fax,	telephone,	etc.).	
2. Orienting the population at large through the media on the possibility 
of resulting infection with CHIKV and on how families and communities 
can contribute to the abatement of the epidemic. Educational materials 
on	 specific	 actions	 to	 prevent	 or	 control	CHIKV	 transmission	 should	 be	
elaborated and distributed by various media (TV, radio, newspapers, local 
organizations, schools, clinics, etc.). It is important to report daily (to the 
press) which communities or neighborhoods are being affected by CHIKV, 
so that residents and local authorities are aware of imminent risk of infection 
and can take appropriate actions (e.g., proper use of repellents, elimination 
of	all	standing	water,	organizing	clean-up	campaigns,	etc.).	Dissemination	
of this information needs to be done in a way that no personal information 
or	identifiers	are	released	to	the	public	at	any	time.
3. Ensuring that infected and febrile persons are protected from mosquito 
bites by using bednets at home and in hospitals. 
4.	Orienting	vector	control	operations	through	real-time	epidemiological	
and entomological assessments of CHIKV transmission, indicating the 
specific	areas	that	need	to	be	treated.		In	areas	where	dengue	is	endemic,	
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knowledge from a retrospective analysis of dengue virus transmission or 
previous experience with dengue viruses should be used to guide vector 
control operations. 
5.	 Applying	 effective	 vector	 control	measures.	 	 An	 epidemic	 is	 generally	 a	
series of smaller outbreaks occurring simultaneously in several different 
places within a country (neighborhoods, cities, municipalities, states), where 
the number of disease cases is unusually large.  This means that epidemic 
control measures may need to be applied concurrently in several locations. 
Large-area	control	of	mosquito	populations	over	short	periods	by	spraying	
insecticides	 from	 truck-	 or	 aircraft-mounted	 equipment	 has	 not	 proven	
effective	in	reducing	dengue	transmission.		Large-scale	outdoor	application	
of	pesticides	may	be	beneficial	when	used	in	conjunction	with	other	control	
measures as part of an integrated mosquito control program.76 Therefore, 
effective vector control measures to be applied during an epidemic are 
similar	to	those	recommended	for	area-wide	CHIKV	containment	(above)	
and dengue virus outbreaks.66 The main difference is that they should be 
simultaneously applied in many areas to abate individual outbreaks.
a.	 Geo-reference	each	CHIKV	case	to	the	level	of	operational	control	areas.	
In the case of endemic areas, conduct the retrospective epidemiological 
study	 at	 this	 level,	 so	 that	 stratification	 serves	 operational	 purposes.	
Use	Geographical	 Information	System	 (GIS)	 to	map	operational	units,	
make and distribute maps of disease incidence, and spatially monitor 
the epidemic.
b. Divide the target area (e.g., state, municipality) into relatively uniform 
areas	(operational	control	areas)	that	will	be	treated	using	an	area-wide	
approach	 (neighborhoods	 with	 2,000−5,000	 persons;	 census	 areas,	
zip-codes,	 etc.).	 	 All	 premises,	 businesses	 and	 other	 areas	 (parks,	
cemeteries, abandoned lots, areas along creeks, illegal dumps, etc.) will 
be simultaneously treated within a few days. This operational division 
of the space should be conducted well in advance of an eventual 
introduction of CHIKV.
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c.	 Area-wide	 vector	 control	 measures	 imply	 having	 sufficiently	 trained	
personnel, equipment, and supplies to treat the environment where 
Aedes	 mosquitoes	 are	 being	 produced.	 By	 significantly	 reducing	
mosquito adults (using adulticides) and the production of new adult 
mosquitoes (source reduction and elimination, larvicides) in a particular 
area, the transmission cycle could be interrupted, and CHIKV could be 
driven to extinction. This scenario is possible only if the number of biting 
mosquitoes is dramatically reduced for the length of time it takes for 
humans and vectors to become clear of CHIKV. For this reason, vector 
control	measures	need	to	achieve	a	very	high	efficiency,	as	measured	by	
the elimination of an extremely large proportion of vector mosquitoes.
Limi ta t ions  o f  Vector  Cont ro l
Vector	 population	 reduction	 and	 the	 associated	 reduction	 of	 vector-human	
contact should be correlated with reduced virus transmission and reduced 
human disease.  In order to interrupt an outbreak, however, vector population 
reduction must be immediate, substantial, and sustained.  Adult mosquitoes 
will continue to emerge and replace adult mosquitoes killed by adulticides. 
Therefore, it is essential to maintain IVM programs with complete coverage 
and repeated treatments. In addition to the presence of mosquito control 
professionals and an active IVM program, it is important to maintain the 
support and cooperation of all members of society.67
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Object i ves       
The aim of this meeting was to assemble a technical advisory group to review 
and adapt a preliminary draft of “Preparedness and Response for Chikungunya 
Virus Introduction in the Americas”. The technical advisory group included 
experts in various fields from the Americas, including epidemiologists, 
clinicians, entomologists, laboratory personnel, and communication specialists. 
After discussing the document’s various chapters, these experts submitted 
changes, additions, and rewrites that they considered appropriate to make the 
guidelines factual and relevant to all countries in the Region. The guidelines 
are meant to be a useful tool that can be adapted and applied by each Member 
Country in establishing the most appropriate strategies for the prevention and 
control of Chikungunya virus in the Americas.
Agenda 
Wednesday, 7/21/10  
8:30	–	9:00						Reception	for	participants
9:00	–	9:30	 Welcome	and	presentation	of	the	meeting’s	objectives	 
and working dynamics
 CDC (Roger Nasci) and PAHO/WHO  
(Otavio Oliva, Luz Maria Vilca) 
9:30	–	10:15				Chikungunya	Virus:	Clinical	and	Epidemiological	aspects.	
 CDC (Ann Powers) 
 Break
10:45	–	11:30	 Laboratory	Diagnosis	of	Chikungunya	virus:	 
An overview CDC (Robert Lanciotti)
Appendix I.  Meeting of the Technical Advisory Group  
of Preparedness and Response for Chikungunya 
Virus Introduction in the Americas
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11:30–12:30				Impact	of	a	Chikungunya	outbreak	on	public	health:	
Experience of La Réunion
 FRANCE, Laveran Military Hospital (Fabrice Simon)
 Lunch 
13:30–14:30	 Chikungunya	cases	identified	in	the	Americas:	USA,	Canada,	
and French Territories
 CDC (Erin Staples)
 CANADA, National Microbiology Laboratory, WHOCC 
(Michael Drebot)
	 FRENCH	TERRITORIES	(Philippe	Quenel)
14:30	–	15:15		Round	table:	Control	of	Aedes aegypti in	the	Americas:	what	
has worked and what has not 
 CDC (Roberto Barrera)
 BRAZIL Ministry of Health (Irma Braga) 
 CDC (Harry Savage) 
 PAHO/WHO (José Luis San Martín)                
 PAHO/WHO (Chris Frederickson)
 Break
15:45	–	16:15	 Assignment	 of	 work	 groups	 and	 review	 of	 goals	 for	 groups	
(five	 working	 groups	 were	 formed	 for	 reviewing	 the	 draft	
guideline “Preparedness and Response for Chikungunya Virus 
Introduction	in	the	Americas”):
-	 Epidemiological	 Aspects	 (Epidemiology,	 Surveillance,	 and	
Outbreak Response chapters)
-	 Clinical	aspects	(Clinical,	Case	Management	chapters)
-	 Laboratory	(Laboratory	Chapter)
-	 Entomology	(Vector	Surveillance	and	Control	chapters)
-	 Communications	(Communications	Chapter)
16:15	–	17:45	 Groups	meet	to	decide	on	approach	(Coordinator,	Presenter)
136 137
Thursday, 7/22/10 
8:30	–	10:00	 Working	groups	(Cont.)	
 Break
10:30	–	12:30	 Working	groups	(Cont.)		
 Lunch 
13:30	–	15:00	 Working	groups	(Cont.)		
 Break
15:30	–	17:00	 Make	changes	to	draft	guidelines	(edit	manuscript)	and	meet	
to draft presentations of proposed changes
Friday, 7/23/10 
8:30	–	09:00	 Groups	meet	to	finalize	draft	presentation	 
of proposed changes
 Break 
9:30	–	11:30	 Group	presentations	
11:30	–	12:30	 Group	presentations	
 Lunch 
13.30	–	14.30	 Additional	changes	to	the	draft	guideline	(final	edits	to	
manuscript)
 Break 
15.00	–	16.00		Wrap-up	and	next	steps
 CDC (Roger Nasci) and PAHO/WHO (Otavio Oliva)
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List of  Participants       
Pan  Amer ican  Hea l th  Organ i za t ion : 
Dr. Otavio Oliva (HSD/IR/V)
Dr. José Luis San Martín (HSD/IR/D)
Dr. Luz Ma. Vilca (HSD/IR/V)
Ms. Olivia Brathwaite (PWR/PAN)
Ms. Vivien Lewis (HSD/IR/V)
Part i c ipants  by  Work ing  Group:
A . Ep idemio logica l  su rve i l l ance : 
Dr. Andrea Olea, Chile (Ministry of Health) 
Dr. Diana Patricia Rojas, Colombia (Ministry of Health,  
Instituto Nacional de Salud) 
Dr. Yeni Herrera, Peru (Ministry of Health)
Dr.	Philippe	Quenel,	Martinique.	(CIRE,	Institut	de	Veille	Sanitaire)
Dr. Joel Montgomery, Peru (NMRCD)
Dr.	Luz	Maria	Vilca,	USA	(PAHO,	WDC)
Dr.	Francisco	Alvarado-Ramy,	USA	 
(Division	of	Global	Migration	and	Quarantine,	CDC)
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B. Laboratory : 
Dr. Delia Enria, Argentina (Instituto Nacional de Enfermedades Virales 
Humanas “Dr Julio I. Maiztegui”)
Dr. Guadalupe Guzmán, Cuba (Instituto Pedro Kourí, WHOCC)
Dr.	Pedro	Vasconcelos:	Brazil	(Instituto	Evandro	Chagas,	WHOCC)
Dr. Michael A. Drebot, Canada (Science Technology and Core Services 
National Microbiology Laboratory, Public Health Agency of Canada, 
WHOCC)
Dr.	Ann	Powers,	USA	(Arboviral	Diseases	Branch,	DVBD,	CDC)	
Dr.	Robert	Lanciotti,	USA	(Arboviral	Diseases	Branch,	DVBD,	CDC)
Dr. César Cabezas, Peru (Instituto Nacional de Salud) 
Dr. Erick Halsey, Peru (NMRC, Virology Department) 
Dr.	Otavio	Oliva,	USA	(PAHO,	WDC)
C. Entomology : 
Dr. Ima Aparecida Braga, Brazil (Secretariat of Health) 
Dr. Juan Arredondo, Mexico (Secretariat of Health)
Dr.	Roger	Nasci,	USA		(Arboviral	Diseases	Branch,	DVBD,	CDC)
Dr.	Harry	Savage,	USA	(Arboviral	Diseases	Branch,	DVBD,	CDC)
Dr. Roberto Barrera, Puerto Rico (Dengue Branch, CDC, WHOCC)
Dr.	Christian	Frederickson,	Trinidad	and	Tobago	(PAHO-CAREC)
Dr. José Luis San Martín, Panama (PAHO, Panamá)
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D. C l in i ca l  Management : 
Dr.	Erin	Staples,	USA	(Arboviral	Diseases	Branch,	DVBD,	CDC)
Dr. Eric Martínez, Cuba (Instituto Pedro Kourí, WHOCC)
Dr. Ernesto Pleites, El Salvador (Ministry of Health, Hospital Nacional de Niños 
Benjamín Bloom)
Dr. Rivaldo Venancio Da Cunha, Brazil (Secretariat of Health)
Dr. Fabrice Simon, France (Department of Infectious Diseases and Tropical 
Medicine. Laveran Military Hospital)
Dr. Iris Villalobos Chacon, Venezuela (Secretaria de Salud)
Dr.	Roser	Gonzalez,	USA	(PAHO,	WDC)
E. Soc ia l  Communicat ion : 
Lic. Xinia Bustamante, Costa Rica (PAHO/WHO, Costa Rica)
Dr.	Carmen	Pérez:	Puerto	Rico	(Dengue	Branch,	CDC,	WHOCC)
Mr.	Lee	Smith,	USA	(Division	of	Global	Migration	and	Quarantine,	CDC)
Dr. Marco Fidel Suárez, Bolivia (PAHO/WHO Bolivia)
Dr.	Emily	Zielinski-Gutierrez,	USA	(DVBD,	CDC)	(Final	revision)
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